STOCK TITAN

Kraig Biocraft: $8.11M deficit, going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Kraig Biocraft Laboratories, Inc. reported $3,000 in revenue for both the three- and nine-month periods ended September 30, 2026. Third-quarter net loss was $1,243,496, compared with $1,509,566 a year earlier; nine-month net loss was $3,095,751 versus $2,835,732. Nine-month operating cash used was $1,722,595, compared with $1,339,483, and research and development expense was $263,354 versus $97,007.

Cash and cash equivalents were $2,783,802 at September 30, 2026, compared with $1,790,236 at December 31, 2025. Working capital deficiency was $8,110,368; the company said these conditions raised substantial doubt about its ability to continue as a going concern, which depends on raising additional capital and implementing its business plan. Under a standby equity purchase agreement granting the company rights to sell up to $10 million of common stock, KBLB sold 25,364,093 shares for $2,772,547 during the nine months. Class A shares outstanding were 1,122,984,957 as of November 16, 2026.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • Moderate pointThird-quarter net loss fell to $1,243,496 from $1,509,566 a year earlier.

Negative

  • Major pointManagement cited a $8,110,368 working-capital deficiency in its going-concern warning.
  • Moderate pointNine-month net loss rose to $3,095,751 from $2,835,732.
  • Moderate pointNine-month operating cash use increased to $1,722,595 from $1,339,483.

Filing Explained

The filing reports that Kraig Biocraft had issued 5,000,000 shares to a consultant for services on September 2, 2026, valued at $400,000; this completed issuance increases the share count and reduces existing holders’ percentage ownership.

Revenue $3,000 For each of the three- and nine-month periods ended September 30, 2026
Third-quarter net loss $1,243,496 loss Three months ended September 30, 2026; $1,509,566 loss in 2025
Nine-month net loss $3,095,751 loss Nine months ended September 30, 2026; $2,835,732 loss in 2025
Cash used in operating activities $1,722,595 Nine months ended September 30, 2026; $1,339,483 used in 2025
Cash and cash equivalents $2,783,802 As of September 30, 2026; $1,790,236 as of December 31, 2025
Working capital deficiency $8,110,368 As of September 30, 2026
Common shares sold 25,364,093 shares Sold under the standby equity purchase agreement during the nine months ended September 30, 2026
Cash proceeds from common stock sales $2,772,547 Nine months ended September 30, 2026
going concern financial
"substantial doubt about its ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
Standby Equity Purchase Agreement financial
"entered into a Standby Equity Purchase Agreement with an investor"
A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.
working capital deficiency financial
"working capital deficiency of $8,110,368"
Working capital deficiency occurs when a company's short-term resources—cash, inventory and money owed to it—are less than its short-term obligations like bills, wages and debt coming due. Like a household that has more monthly bills than money in the bank, this situation signals a liquidity squeeze that may force borrowing, asset sales or cuts to dividends, and it matters to investors because it raises the risk of operational disruption and reduced shareholder returns.
cashless exercise financial
"in connection with the cashless exercise of 6,000,000 warrants"
A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.
anti-dilutive financial
"because their inclusion is anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
performance obligations financial
"The Company’s performance obligations consist of the delivery of the Company’s products"
Performance obligations are the specific promises a company makes to deliver goods or services to a customer under a contract, treated as separate deliverables when a customer can benefit from them on their own. Investors care because these promises determine when and how much revenue a company records — like breaking a bundled purchase into separate billable parts — which affects reported earnings, growth trends and the clarity of future cash flows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and net loss did KBLB report for the third quarter of 2026?

KBLB reported $3,000 in revenue for both the three- and nine-month periods ended September 30, 2026. Third-quarter net loss was $1,243,496, compared with $1,509,566 a year earlier; nine-month net loss was $3,095,751, compared with $2,835,732.

How much did KBLB raise through its standby equity purchase agreement?

KBLB sold 25,364,093 shares for total cash proceeds of $2,772,547 during the nine months ended September 30, 2026. The agreement gives the company rights to sell up to $10 million of common stock.

How many KBLB shares were outstanding as of November 16, 2026?

KBLB reported 1,122,984,957 Class A common shares, zero Class B common shares and three preferred shares outstanding as of November 16, 2026.

Why did KBLB report substantial doubt about its ability to continue as a going concern?

KBLB cited a $8,110,368 working capital deficiency, a $7,502,437 stockholders’ deficiency and $1,722,595 of cash used in operations for the nine months ended September 30, 2026. The company said continued operations depend on raising additional capital and implementing its business plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0001413119 Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited 0001413119 2026-01-01 2026-09-30 0001413119 us-gaap:CommonClassAMember 2026-11-16 0001413119 us-gaap:CommonClassBMember 2026-11-16 0001413119 2026-09-30 0001413119 2025-12-31 0001413119 us-gaap:NonrelatedPartyMember 2026-09-30 0001413119 us-gaap:NonrelatedPartyMember 2025-12-31 0001413119 us-gaap:RelatedPartyMember 2026-09-30 0001413119 us-gaap:RelatedPartyMember 2025-12-31 0001413119 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001413119 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001413119 us-gaap:CommonClassAMember 2026-09-30 0001413119 us-gaap:CommonClassAMember 2025-12-31 0001413119 us-gaap:CommonClassBMember 2026-09-30 0001413119 us-gaap:CommonClassBMember 2025-12-31 0001413119 2025-01-01 2025-12-31 0001413119 us-gaap:CommonClassAMember 2026-01-01 2026-09-30 0001413119 us-gaap:CommonClassAMember 2025-01-01 2025-12-31 0001413119 us-gaap:CommonClassBMember 2026-01-01 2026-09-30 0001413119 us-gaap:CommonClassBMember 2025-01-01 2025-12-31 0001413119 2026-07-01 2026-09-30 0001413119 2025-07-01 2025-09-30 0001413119 2025-01-01 2025-09-30 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-06-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2026-06-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2026-06-30 0001413119 KBLB:CommonStockToBeIssuedMember 2026-06-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001413119 us-gaap:RetainedEarningsMember 2026-06-30 0001413119 2026-06-30 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-12-31 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-12-31 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2025-12-31 0001413119 KBLB:CommonStockToBeIssuedMember 2025-12-31 0001413119 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001413119 us-gaap:RetainedEarningsMember 2025-12-31 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-06-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-06-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2025-06-30 0001413119 KBLB:CommonStockToBeIssuedMember 2025-06-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001413119 us-gaap:RetainedEarningsMember 2025-06-30 0001413119 2025-06-30 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-12-31 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2024-12-31 0001413119 KBLB:CommonStockToBeIssuedMember 2024-12-31 0001413119 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001413119 us-gaap:RetainedEarningsMember 2024-12-31 0001413119 2024-12-31 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-07-01 2026-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2026-07-01 2026-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2026-07-01 2026-09-30 0001413119 KBLB:CommonStockToBeIssuedMember 2026-07-01 2026-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001413119 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2026-01-01 2026-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2026-01-01 2026-09-30 0001413119 KBLB:CommonStockToBeIssuedMember 2026-01-01 2026-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001413119 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-07-01 2025-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-07-01 2025-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2025-07-01 2025-09-30 0001413119 KBLB:CommonStockToBeIssuedMember 2025-07-01 2025-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001413119 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-01-01 2025-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2025-01-01 2025-09-30 0001413119 KBLB:CommonStockToBeIssuedMember 2025-01-01 2025-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001413119 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2026-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2026-09-30 0001413119 KBLB:CommonStockToBeIssuedMember 2026-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001413119 us-gaap:RetainedEarningsMember 2026-09-30 0001413119 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-09-30 0001413119 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2025-09-30 0001413119 KBLB:CommonStockToBeIssuedMember 2025-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001413119 us-gaap:RetainedEarningsMember 2025-09-30 0001413119 2025-09-30 0001413119 KBLB:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-09-30 0001413119 KBLB:GlobalSilkSolutionsMember 2026-09-30 0001413119 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001413119 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001413119 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001413119 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001413119 us-gaap:ConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001413119 us-gaap:ConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001413119 KBLB:CommonStockPayableMember 2026-01-01 2026-09-30 0001413119 KBLB:CommonStockPayableMember 2025-01-01 2025-12-31 0001413119 srt:MinimumMember us-gaap:WarrantMember 2026-09-30 0001413119 srt:MinimumMember us-gaap:WarrantMember 2025-12-31 0001413119 srt:MaximumMember us-gaap:WarrantMember 2026-09-30 0001413119 srt:MaximumMember us-gaap:WarrantMember 2025-12-31 0001413119 us-gaap:EmployeeStockOptionMember 2026-09-30 0001413119 us-gaap:EmployeeStockOptionMember 2025-12-31 0001413119 us-gaap:FairValueInputsLevel1Member KBLB:InvestmentInGoldMember 2026-09-30 0001413119 us-gaap:FairValueInputsLevel2Member KBLB:InvestmentInGoldMember 2026-09-30 0001413119 us-gaap:FairValueInputsLevel3Member KBLB:InvestmentInGoldMember 2026-09-30 0001413119 KBLB:InvestmentInGoldMember 2026-09-30 0001413119 us-gaap:FairValueInputsLevel1Member KBLB:InvestmentInGoldMember 2025-12-31 0001413119 us-gaap:FairValueInputsLevel2Member KBLB:InvestmentInGoldMember 2025-12-31 0001413119 us-gaap:FairValueInputsLevel3Member KBLB:InvestmentInGoldMember 2025-12-31 0001413119 KBLB:InvestmentInGoldMember 2025-12-31 0001413119 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2026-09-30 0001413119 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2026-09-30 0001413119 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2026-09-30 0001413119 us-gaap:MoneyMarketFundsMember 2026-09-30 0001413119 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2025-12-31 0001413119 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2025-12-31 0001413119 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2025-12-31 0001413119 us-gaap:MoneyMarketFundsMember 2025-12-31 0001413119 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001413119 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001413119 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001413119 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001413119 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001413119 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001413119 us-gaap:AutomobilesMember 2026-09-30 0001413119 us-gaap:AutomobilesMember 2025-12-31 0001413119 KBLB:LaboratoryEquipmentMember 2026-09-30 0001413119 KBLB:LaboratoryEquipmentMember 2025-12-31 0001413119 KBLB:LaboratoryEquipmentMember srt:MinimumMember 2026-09-30 0001413119 KBLB:LaboratoryEquipmentMember srt:MaximumMember 2026-09-30 0001413119 us-gaap:OfficeEquipmentMember 2026-09-30 0001413119 us-gaap:OfficeEquipmentMember 2025-12-31 0001413119 us-gaap:OfficeEquipmentMember srt:MinimumMember 2026-09-30 0001413119 us-gaap:OfficeEquipmentMember srt:MaximumMember 2026-09-30 0001413119 us-gaap:LeaseholdImprovementsMember 2026-09-30 0001413119 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001413119 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2026-09-30 0001413119 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2026-09-30 0001413119 KBLB:OperatingLeaseAgreementsMember 2026-01-01 2026-09-30 0001413119 2019-09-05 0001413119 KBLB:OperatingLeaseAgreementsMember 2021-07-01 2022-09-30 0001413119 KBLB:OperatingLeaseAgreementsMember 2022-10-01 2023-09-30 0001413119 KBLB:AdoptionOfNewGuidanceMember 2026-09-30 0001413119 KBLB:OperatingLeaseAgreementsMember 2023-10-01 2024-12-31 0001413119 KBLB:OperatingLeaseAgreementsMember 2024-10-01 2025-12-31 0001413119 KBLB:AdoptionOfNewGuidanceMember KBLB:OctoberOneTwoThosuandTwentyFourThroughDecemberThrityOneTwoThosuandTwentyFiveMember 2026-09-30 0001413119 KBLB:AdoptionOfNewGuidanceMember KBLB:OctoberOneTwoThousandTwentyFiveThroughSeptemberThrityTwoThosuandTwentyEightMember 2026-09-30 0001413119 KBLB:SocialistRepublicOfVietnamMember 2021-07-01 0001413119 2024-01-31 0001413119 2024-01-31 2024-01-31 0001413119 2024-09-20 0001413119 2026-01-01 0001413119 2026-03-31 0001413119 2026-04-23 0001413119 2026-04-28 0001413119 2026-05-13 0001413119 2026-08-13 0001413119 KBLB:LeaseTermOneMember KBLB:SeptemberFiveTwoThousandNineteenMember 2019-09-05 2019-09-05 0001413119 KBLB:LeaseTermTwoMember KBLB:SeptemberFiveTwoThousandNineteenMember 2019-09-05 2019-09-05 0001413119 KBLB:LeaseTermThreeMember KBLB:SeptemberFiveTwoThousandNineteenMember 2019-09-05 2019-09-05 0001413119 KBLB:LeaseTermOneMember KBLB:SeptemberTwentyTwoThousandTwentyFourMember 2024-09-20 2024-09-20 0001413119 KBLB:LeaseTermTwoMember KBLB:SeptemberTwentyTwoThousandTwentyFourMember 2024-09-20 2024-09-20 0001413119 KBLB:SeptemberTwentyTwoThousandTwentyFourMember KBLB:LeaseTermThreeMember 2024-09-20 2024-09-20 0001413119 KBLB:LeaseTermOneMember KBLB:JanuaryOneTwoThousandAndTwentySixMember 2026-01-01 2026-01-01 0001413119 KBLB:LeaseTermTwoMember KBLB:JanuaryOneTwoThousandAndTwentySixMember 2026-01-01 2026-01-01 0001413119 KBLB:LeaseTermOneMember KBLB:MarchThirtyOneTwoThousandAndTwentySixMember 2026-03-31 2026-03-31 0001413119 KBLB:LeaseTermTwoMember KBLB:MarchThirtyOneTwoThousandAndTwentySixMember 2026-03-31 2026-03-31 0001413119 KBLB:LeaseTermThreeMember KBLB:MarchThirtyOneTwoThousandAndTwentySixMember 2026-03-31 2026-03-31 0001413119 KBLB:LeaseTermOneMember KBLB:AprilTwentyThreeTwoThousandAndTwentySixMember 2026-04-23 2026-04-23 0001413119 KBLB:LeaseTermTwoMember KBLB:AprilTwentyThreeTwoThousandAndTwentySixMember 2026-04-23 2026-04-23 0001413119 KBLB:LeaseTermThreeMember KBLB:AprilTwentyThreeTwoThousandAndTwentySixMember 2026-04-23 2026-04-23 0001413119 KBLB:LeaseTermFourMember KBLB:AprilTwentyThreeTwoThousandAndTwentySixMember 2026-04-23 2026-04-23 0001413119 KBLB:LeaseTermFiveMember KBLB:AprilTwentyThreeTwoThousandAndTwentySixMember 2026-04-23 2026-04-23 0001413119 KBLB:LeaseTermOneMember KBLB:AprilTwentyEightTwoThousandAndTwentySixMember 2026-04-28 2026-04-28 0001413119 KBLB:LeaseTermTwoMember KBLB:AprilTwentyEightTwoThousandAndTwentySixMember 2026-04-28 2026-04-28 0001413119 KBLB:LeaseTermOneMember KBLB:MayThirteenTwoThousandAndTwentySixMember 2026-05-13 2026-05-13 0001413119 KBLB:LeaseTermTwoMember KBLB:MayThirteenTwoThousandAndTwentySixMember 2026-05-13 2026-05-13 0001413119 KBLB:LeaseTermThreeMember KBLB:MayThirteenTwoThousandAndTwentySixMember 2026-05-13 2026-05-13 0001413119 KBLB:LeaseTermOneMember KBLB:AugustThirteenTwoThousandAndTwentySixMember 2026-08-13 2026-08-13 0001413119 KBLB:LeaseTermTwoMember KBLB:AugustThirteenTwoThousandAndTwentySixMember 2026-08-13 2026-08-13 0001413119 KBLB:LeaseTermThreeMember KBLB:AugustThirteenTwoThousandAndTwentySixMember 2026-08-13 2026-08-13 0001413119 KBLB:LeaseTermFourMember KBLB:AugustThirteenTwoThousandAndTwentySixMember 2026-08-13 2026-08-13 0001413119 srt:ChiefExecutiveOfficerMember us-gaap:UnsecuredDebtMember 2016-09-06 2020-12-01 0001413119 srt:ChiefExecutiveOfficerMember us-gaap:UnsecuredDebtMember 2020-12-01 0001413119 srt:ChiefExecutiveOfficerMember 2022-01-26 2022-01-26 0001413119 srt:ChiefExecutiveOfficerMember 2025-08-26 2025-08-26 0001413119 srt:ChiefExecutiveOfficerMember 2025-12-16 2025-12-16 0001413119 srt:ChiefExecutiveOfficerMember 2026-09-30 0001413119 srt:ChiefExecutiveOfficerMember 2025-12-31 0001413119 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001413119 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-09-30 0001413119 srt:ChiefExecutiveOfficerMember 2025-09-30 0001413119 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0001413119 us-gaap:CommonStockMember 2025-01-21 2025-01-21 0001413119 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001413119 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001413119 us-gaap:CommonStockMember 2026-09-02 2026-09-02 0001413119 us-gaap:CommonStockMember 2026-09-02 0001413119 us-gaap:CommonStockMember 2025-07-09 2025-07-09 0001413119 us-gaap:CommonStockMember 2025-07-09 0001413119 us-gaap:CommonStockMember 2025-07-16 2025-07-16 0001413119 us-gaap:CommonStockMember 2025-07-16 0001413119 2026-05-04 0001413119 2025-03-14 0001413119 2025-07-01 0001413119 KBLB:WarrantAndOptionMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantAndOptionMember 2025-12-31 0001413119 KBLB:WarrantAndOptionMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantAndOptionMember 2026-09-30 0001413119 us-gaap:CommonStockMember 2021-03-25 0001413119 2021-03-25 0001413119 us-gaap:CommonStockMember 2021-03-25 2021-03-25 0001413119 KBLB:TenYearOptionMember 2026-01-15 2026-01-15 0001413119 KBLB:TenYearOptionMember 2026-01-15 0001413119 KBLB:SevenYearOptionMember 2025-10-22 2025-10-22 0001413119 KBLB:SevenYearOptionMember 2025-10-22 0001413119 KBLB:SevenYearOptionMember 2026-07-01 2026-09-30 0001413119 KBLB:VestOptionOneMember 2025-10-22 2025-10-22 0001413119 KBLB:VestOptionTwoMember 2025-10-22 2025-10-22 0001413119 KBLB:FiveYearOptionOneMember 2025-07-10 2025-07-10 0001413119 KBLB:FiveYearOptionOneMember 2025-07-10 0001413119 KBLB:FiveYearOptionOneMember 2025-01-01 2025-12-31 0001413119 KBLB:FiveYearOptionTwoMember 2025-07-10 2025-07-10 0001413119 KBLB:FiveYearOptionTwoMember 2025-01-01 2025-12-31 0001413119 KBLB:SevenYearOptionOneMember 2025-04-01 2025-04-01 0001413119 KBLB:SevenYearOptionOneMember 2025-04-01 0001413119 KBLB:TwentyFourMonthsOptionMember 2025-04-01 0001413119 KBLB:ThirthySixMonthsOptionMember 2025-04-01 0001413119 KBLB:FourthyEightMonthsOptionMember 2025-04-01 0001413119 KBLB:SevenYearOptionTwoMember 2024-10-01 2024-10-01 0001413119 KBLB:SevenYearOptionTwoMember 2024-10-01 0001413119 KBLB:SevenYearOptionTwoMember 2026-01-01 2026-09-30 0001413119 KBLB:SevenYearOptionThreeMember 2024-08-06 2024-08-06 0001413119 KBLB:SevenYearOptionThreeMember 2024-08-06 0001413119 KBLB:SevenYearOptionThreeMember 2026-01-01 2026-09-30 0001413119 KBLB:SevenYearOptionFourMember 2024-08-06 2024-08-06 0001413119 KBLB:SevenYearOptionFourMember 2024-08-06 0001413119 KBLB:SevenYearOptionFourMember 2026-01-01 2026-09-30 0001413119 KBLB:SevenYearOptionFiveMember 2024-08-06 2024-08-06 0001413119 KBLB:SevenYearOptionFiveMember 2024-08-06 0001413119 KBLB:SevenYearOptionFiveMember 2025-01-01 2025-12-31 0001413119 KBLB:SevenYearOptionSixMember 2024-08-06 2024-08-06 0001413119 KBLB:SevenYearOptionSixMember 2024-08-06 0001413119 KBLB:SevenYearOptionSixMember 2026-01-01 2026-09-30 0001413119 KBLB:FiveYearOptionThreeMember 2023-12-13 2023-12-13 0001413119 KBLB:FiveYearOptionThreeMember 2023-12-13 0001413119 KBLB:FiveYearOptionThreeMember 2026-01-01 2026-09-30 0001413119 KBLB:FiveYearOptionFourMember 2023-12-13 2023-12-13 0001413119 KBLB:FiveYearOptionFourMember 2023-12-13 0001413119 KBLB:FiveYearOptionFourMember 2026-01-01 2026-09-30 0001413119 us-gaap:CommonClassAMember 2009-02-16 2009-02-16 0001413119 us-gaap:CommonClassAMember 2009-02-16 0001413119 us-gaap:CommonClassBMember 2009-02-16 2009-02-16 0001413119 us-gaap:CommonClassBMember 2009-02-16 0001413119 2009-02-16 2009-02-16 0001413119 2009-02-16 0001413119 us-gaap:SeriesAPreferredStockMember 2013-12-17 0001413119 us-gaap:SeriesAPreferredStockMember 2024-03-26 0001413119 us-gaap:SeriesAPreferredStockMember KBLB:MrKimThompsonMember 2024-03-26 0001413119 us-gaap:SeriesAPreferredStockMember KBLB:MrKimThompsonMember 2024-03-26 2024-03-26 0001413119 us-gaap:WarrantMember 2026-09-30 0001413119 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantOneMember 2026-09-30 0001413119 KBLB:WarrantOneMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantTwoMember 2026-09-30 0001413119 KBLB:WarrantTwoMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantThreeMember 2026-09-30 0001413119 KBLB:WarrantThreeMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantFourMember 2026-09-30 0001413119 KBLB:WarrantFourMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantFiveMember 2026-09-30 0001413119 KBLB:WarrantFiveMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantSixMember 2026-09-30 0001413119 KBLB:WarrantSixMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantSevenMember 2026-09-30 0001413119 KBLB:WarrantSevenMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantEightMember 2026-09-30 0001413119 KBLB:WarrantEightMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantNineMember 2026-09-30 0001413119 KBLB:WarrantNineMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantTenMember 2026-09-30 0001413119 KBLB:WarrantTenMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantElevenMember 2026-09-30 0001413119 KBLB:WarrantElevenMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantTwelveMember 2026-09-30 0001413119 KBLB:WarrantTwelveMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantThirteenMember 2026-09-30 0001413119 KBLB:WarrantThirteenMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantFourteenMember 2026-09-30 0001413119 KBLB:WarrantFourteenMember 2026-01-01 2026-09-30 0001413119 KBLB:WarrantFifteenMember 2026-09-30 0001413119 KBLB:WarrantFifteenMember 2026-01-01 2026-09-30 0001413119 us-gaap:WarrantMember 2025-12-31 0001413119 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantOneMember 2025-12-31 0001413119 KBLB:WarrantOneMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantTwoMember 2025-12-31 0001413119 KBLB:WarrantTwoMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantThreeMember 2025-12-31 0001413119 KBLB:WarrantThreeMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantFourMember 2025-12-31 0001413119 KBLB:WarrantFourMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantFiveMember 2025-12-31 0001413119 KBLB:WarrantFiveMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantSixMember 2025-12-31 0001413119 KBLB:WarrantSixMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantSevenMember 2025-12-31 0001413119 KBLB:WarrantSevenMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantEightMember 2025-12-31 0001413119 KBLB:WarrantEightMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantNineMember 2025-12-31 0001413119 KBLB:WarrantNineMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantTenMember 2025-12-31 0001413119 KBLB:WarrantTenMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantElevenMember 2025-12-31 0001413119 KBLB:WarrantElevenMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantTwelveMember 2025-12-31 0001413119 KBLB:WarrantTwelveMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantThirteenMember 2025-12-31 0001413119 KBLB:WarrantThirteenMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantFourteenMember 2025-12-31 0001413119 KBLB:WarrantFourteenMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantFifteenMember 2025-12-31 0001413119 KBLB:WarrantFifteenMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantSixteenMember 2025-12-31 0001413119 KBLB:WarrantSixteenMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantSeventeenMember 2025-12-31 0001413119 KBLB:WarrantSeventeenMember 2025-01-01 2025-12-31 0001413119 KBLB:WarrantEighteenMember 2025-12-31 0001413119 KBLB:WarrantEighteenMember 2025-01-01 2025-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2010-11-10 2010-11-10 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2015-01-01 2015-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2016-01-01 2016-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2017-01-01 2017-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2019-01-01 2019-01-01 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember srt:ScenarioForecastMember 2026-01-01 2026-12-31 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2015-01-20 2015-01-20 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2015-01-20 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2015-05-28 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2015-12-31 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2016-01-14 2016-01-14 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2016-01-14 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2019-08-08 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2019-04-26 2019-04-26 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2019-08-15 2019-08-15 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember us-gaap:SubsequentEventMember 2026-10-12 2026-10-12 0001413119 KBLB:MrJonathanRRiceMember KBLB:EmploymentAgreementMember 2026-09-30 0001413119 KBLB:MrJonathanRRiceMember KBLB:EmploymentAgreementMember 2025-12-31 0001413119 KBLB:EmploymentAgreementMember KBLB:MrKennethLeMember 2025-01-14 2025-01-14 0001413119 KBLB:EmploymentAgreementMember KBLB:MrKennethLeMember 2025-01-14 0001413119 2024-01-01 2024-12-31 0001413119 KBLB:FiveYearOptionsOneMember 2023-12-13 2023-12-13 0001413119 KBLB:FiveYearOptionsOneMember 2023-12-13 0001413119 KBLB:FiveYearOptionsOneMember 2026-09-30 0001413119 KBLB:FiveYearOptionsOneMember 2025-12-31 0001413119 KBLB:OakStreetCommunicationsMember 2026-05-04 2026-05-04 0001413119 KBLB:OakStreetCommunicationsMember 2026-07-30 2026-07-30 0001413119 2026-09-02 2026-09-02 0001413119 KBLB:IntellectualPropertyTransferAgreementMember KBLB:KimThompsonMember 2007-12-26 2007-12-26 0001413119 KBLB:IntellectualPropertyTransferAgreementMember KBLB:KimThompsonMember 2026-09-30 0001413119 KBLB:IntellectualPropertyTransferAgreementMember KBLB:KimThompsonMember 2025-12-31 0001413119 KBLB:IntellectualPropertyTransferAgreementMember KBLB:KimThompsonMember 2026-07-01 2026-09-30 0001413119 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember KBLB:CustomerOneMember 2026-07-01 2026-09-30 0001413119 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember KBLB:CustomerOneMember 2026-01-01 2026-09-30 0001413119 KBLB:StockholderMember 2026-09-30 0001413119 KBLB:StockholderMember 2025-12-31 0001413119 srt:ChiefExecutiveOfficerMember 2024-02-02 0001413119 us-gaap:RelatedPartyMember srt:ChiefExecutiveOfficerMember 2026-09-30 0001413119 us-gaap:RelatedPartyMember srt:ChiefExecutiveOfficerMember 2025-12-31 0001413119 KBLB:SeniorStaffMember 2026-09-30 0001413119 KBLB:SeniorStaffMember 2025-12-31 0001413119 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2026-07-01 2026-09-30 0001413119 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2025-07-01 2025-09-30 0001413119 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2026-01-01 2026-09-30 0001413119 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2025-01-01 2025-09-30 0001413119 us-gaap:SubsequentEventMember 2026-10-06 2026-10-06 0001413119 us-gaap:SubsequentEventMember KBLB:StandbyEquityPurchaseAgreementMember 2026-10-07 2026-10-07 0001413119 KBLB:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-10-14 2026-10-14 0001413119 KBLB:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-10-21 2026-10-21 0001413119 KBLB:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-10-28 2026-10-28 0001413119 KBLB:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-11-03 2026-11-03 0001413119 KBLB:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-11-09 2026-11-09 0001413119 KBLB:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:oz KBLB:Segment utr:sqft utr:sqm xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission File Number: 000-56232

 

KRAIG BIOCRAFT LABORATORIES, INC.

(Exact Name of Registrant as Specified in Charter)

 

Wyoming   83-0459707

(State or Other Jurisdiction

of Incorporation)

 

(I.R.S. Employer

Identification No.)

 

2723 South State St. Suite 150

Ann Arbor, Michigan 48104

(Address of Principal Executive Offices)

 

(734) 619-8066

(Registrant’s telephone number, including area code)

 

 

(Former name and address, if changed since last report)

 

Copies to:

Hunter Taubman Fischer & Li LLC

950 Third Ave., 19th Floor

New York, NY 10022

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
None   -   -

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and emerging growth company in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 16, 2026, there were 1,122,984,957 shares of the issuer’s Class A common stock, no par value per share, outstanding, 0 shares of the issuer’s Class B common stock, no par value per share, outstanding and 3 shares of preferred stock, no par value per share, outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

  Page
   
PART I FINANCIAL INFORMATION  
   
Item 1. Unaudited Condensed Financial Statements:  
   
Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 (Audited) 2
   
Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2026, and 2025 3
   
Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2026 (Unaudited) 4
   
Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2025 (Unaudited) 5
   
Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2026 6
   
Notes to Condensed Consolidated Financial Statements (Unaudited) 7
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 32
   
Item 3. Quantitative and Qualitative Disclosures about Market Risk 41
   
Item 4. Controls and Procedures 41
   
PART II OTHER INFORMATION  
   
Item 1. Legal proceedings 42
   
Item 1A. Risk Factors 42
   
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 42
   
Item 3. Defaults upon Senior Securities 42
   
Item 4. Mine Safety Disclosures 42
   
Item 5. Other information 42
   
Item 6. Exhibits 43

 

1

 

 

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

 

   September 30, 2026   December 31, 2025 
   (Unaudited)     
ASSETS          
Current Assets          
Cash and cash equivalents  $2,783,802   $1,790,236 
Accounts receivable   3,000    - 
Inventories - net   172,761    29,067 
Prepaid expenses   58,140    49,338 
Total Current Assets   3,017,703    1,868,641 
           
Property and Equipment, net   62,621    25,003 
Investment in gold bullions (cost $241,120 and $450,216, respectively)   460,038    494,259 
Operating lease right-of-use asset, net   187,201    170,463 
Security deposit   9,986    7,174 
           
Total Assets  $3,737,549   $2,565,540 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
Current Liabilities          
Accounts payable and accrued expenses  $510,517   $505,111 
Note payable - related party   1,492,000    1,492,000 
Royalty agreement payable - related party   65,292    65,292 
Accounts payable and accrued expenses - related party   8,982,176    8,330,933 
Operating lease liability, current   78,086    51,909 
Total Current Liabilities   11,128,071    10,445,245 
           
Long Term Liabilities          
Operating lease liability, net of current   111,915    119,253 
Total Liabilities   11,239,986    10,564,498 
           
Commitments and Contingencies (Note 7)   -    - 
           
Stockholders’ Deficit          
Preferred stock, no par value; unlimited shares authorized, none, issued and outstanding   -    - 
Preferred stock Series A, no par value; 3 and 3 shares issued and outstanding, respectively   5,237,800    5,237,800 
Common stock Class A, no par value; unlimited shares authorized, 1,120,334,070 and 1,084,010,130 shares issued and outstanding, respectively   34,330,501    31,015,428 
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding   -    - 
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively   22,000    22,000 
Additional paid-in capital   12,712,085    12,434,886 
Accumulated Deficit   (59,804,823)   (56,709,072)
           
Total Stockholders’ Deficit   (7,502,437)   (7,998,958)
           
Total Liabilities and Stockholders’ Deficit  $3,737,549   $2,565,540 

 

2

 

 

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(Unaudited)

 

   September 30, 2026   September 30, 2025   September 30, 2026   September 30, 2025 
   For the Three Months Ended   For the Nine Months Ended 
   September 30, 2026   September 30, 2025   September 30, 2026   September 30, 2025 
Revenue  $3,000   $-   $3,000   $- 
Cost of Revenues   4,320    -    4,320    - 
Gross Loss   (1,320)   -    (1,320)   - 
                     
Operating Expenses                    
General and Administrative   752,243    1,199,955    1,622,190    1,852,841 
Professional Fees   55,719    38,533    196,416    145,193 
Officer’s Salary   193,705    186,157    580,924    557,084 
Research and Development   132,284    9,243    263,354    97,007 
Total Operating Expenses   1,133,951    1,433,888    2,662,884    2,652,125 
                     
Loss from Operations   (1,135,271)   (1,433,888)   (2,664,204)   (2,652,125)
                     
Other Income/(Expenses)                    
Net change in unrealized depreciation on investment in gold bullion   19,386    (30,968)   (34,221)   76,509 
Interest expense   (153,385)   (144,255)   (453,217)   (426,589)
Gain on sale of gold   -    98,427    -    160,896 
Interest income   25,774    1,118    55,891    5,577 
Total Other Income/(Expenses)   (108,225)   (75,678)   (431,547)   (183,607)
                     
Net (Loss) before Provision for Income Taxes   (1,243,496)   (1,509,566)   (3,095,751)   (2,835,732)
                     
Provision for Income Taxes   -    -    -    - 
                     
Net (Loss)  $(1,243,496)  $(1,509,566)  $(3,095,751)  $(2,835,732)
                     
Net Income (Loss) Per Share - Basic and Diluted  $(0.00)  $(0.00)  $(0.00)  $(0.00)
                     
Weighted average number of shares outstanding during the period - Basic and Diluted   1,116,855,809    1,068,264,462    1,106,117,875    1,052,499,052 

 

3

 

 

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Statement of Changes in Stockholders’ Deficit

For the three and nine months ended September 30, 2026

(Unaudited)

 

   Shares   Par   Shares   Par   Shares   Par   Shares   Par   APIC   Deficit   Total 
   Preferred Stock - Series A   Common Stock - Class A   Common Stock - Class B   To be issued       Accumulated     
   Shares   Par   Shares   Par   Shares   Par   Shares   Par   APIC   Deficit   Total 
                                             
Balance, June 30, 2026 (Unaudited)   3   $5,237,800    1,115,334,070   $33,930,501    -   $-    1,122,311   $22,000   $12,619,910   $(58,561,327)   (6,751,116)
                                                        
Warrants issued for services - related parties   -    -    -    -    -    -    -    -    20,318    -    20,318 
                                                        
Warrants issued for services   -    -    -    -    -    -    -    -    42,897    -    42,897 
                                                        
Options issued for services   -    -    -    -    -    -    -    -    10,157    -    10,157 
                                                        
Shares issued in connection with cashless warrants exercise   -    -    -    -    -    -    -    -    -    -    - 
                                                        
Imputed interest - related party   -    -    -    -    -    -    -    -    18,803    -    18,803 
                                                        
Issuance of common stock for services   -    -    5,000,000    400,000    -    -    -    -    -    -    400,000 
                                                        
Net loss for the three months ended September 30, 2026   -    -    -    -    -    -    -    -    -    (1,243,496)   (1,243,496)
                                                        
Balance, September 30, 2026 (Unaudited)   3   $5,237,800    1,120,334,070   $34,330,501    -   $-    1,122,311   $22,000   $12,712,085   $(59,804,823)   (7,502,437)
                                                        
Balance, December 31, 2025 (Audited)   3   $5,237,800    1,084,010,130   $31,015,428    -   $-    1,122,311   $22,000   $12,434,886   $(56,709,072)   (7,998,958)
                                                        
Warrants issued for services - related parties   -    -    -    -    -    -    -    -    60,954    -    60,954 
                                                        
Warrants issued for services   -    -    -    -    -    -    -    -    272,707    -    272,707 
                                                        
Options issued for services   -    -    -    -    -    -    -    -    30,471    -    30,471 
                                                        
Shares issued in connection with cashless warrants exercise   -    -    5,959,847    142,526                        (142,526)        - 
                                                        
Imputed interest - related party   -    -    -    -    -    -    -    -    55,593    -    55,593 
                                                        
Issuance of common stock for services   -    -    5,000,000    400,000    -    -    -    -    -    -    400,000 
                                                        
Issuance of common stock   -    -    25,364,093    2,772,547    -    -    -    -    -    -    2,772,547 
                                                        
Net loss for the nine months ended September 30, 2026   -    -    -    -    -    -    -    -    -    (3,095,751)   (3,095,751)
                                                        
Balance, September 30, 2026 (Unaudited)   3   $5,237,800    1,120,334,070   $34,330,501    -   $-    1,122,311   $22,000   $12,712,085   $(59,804,823)   (7,502,437)

 

4

 

 

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Statement of Changes in Stockholders’ Deficit

For the three and nine months ended September 30, 2025

(Unaudited)

 

   Preferred Stock - Series A   Common Stock - Class A   Common Stock - Class B   To be issued       Accumulated      
   Shares   Par   Shares   Par   Shares   Par   Shares   Par   APIC   Deficit   Total 
                                             
Balance, June 30, 2025 (Audited)   3   $5,237,800    1,052,600,334   $28,446,556    -   $-    1,122,311   $22,000   $12,232,665   $(54,411,885)   (8,472,864)
                                                        
Warrants issued for services - related parties   -    -    -    -    -    -    -    -    47,760    -    47,760 
                                                        
Warrants issued for services   -    -    -    -    -    -    -    -    50,082    -    50,082 
                                                        
Options issued for services   -    -    -    -    -    -    -    -    4,197    -    4,197 
                                                        
Imputed interest - related party   -    -    -    -    -    -    -    -    20,379    -    20,379 
                                                        
Issuance of common stock for services   -    -    10,000,000    834,600    -    -    -    -    -    -    834,600 
                                                        
Issuance of common stock, net of stock offering costs   -    -    13,329,807    1,069,335    -    -    -    -    -    -    1,069,335 
                                                        
Shares issued in connection with cashless warrants exercise   -    -    314,636    12,739                        (12,739)   -    - 
                                                        
Net loss for the three months ended June 30, 2025   -    -    -    -    -    -    -    -    -    (1,509,566)   (1,509,566)
                                                        
Balance, September 30, 2025 (Unaudited)   3   $5,237,800    1,076,244,777   $30,363,230    -   $-    1,122,311   $22,000   $12,342,344   $(55,921,451)   (7,956,077)
                                                        
Balance, December 31, 2024 (Audited)   3   $5,237,800    1,038,374,219   $27,385,611    -   $-    1,122,311   $22,000   $12,290,687   $(53,085,719)   (8,149,621)
                                                        
Warrants issued for services - related parties   -    -    -    -    -    -    -    -    74,760    -    74,760 
                                                        
Warrants issued for services   -    -    -    -    -    -    -    -    121,151    -    121,151 
                                                        
Options issued for services   -    -    -    -    -    -    -    -    12,591    -    12,591 
                                                        
Imputed interest - related party   -    -    -    -    -    -    -    -    60,472    -    60,472 
                                                        
Issuance of common stock for services   -    -    10,000,000    834,600    -    -    -    -    -    -    834,600 
                                                        
Issuance of common stock, net of stock offering costs   -    -    24,316,741    1,950,702    -    -    -    -    (25,000)   -    1,925,702 
                                                        
Issuance of common stock for commitment fee   -    -    1,081,471    100,000    -    -    -    -    (100,000)   -    - 
                                                        
Shares issued in connection with cashless warrants exercise   -    -    2,472,346    92,317    -    -    -    -    (92,317)   -    - 
                                                        
Net loss for the nine months ended September 30, 2025   -    -    -    -    -    -    -    -    -    (2,835,732)   (2,835,732)
                                                        
Balance, September 30, 2025 (Unaudited)   3   $5,237,800    1,076,244,777   $30,363,230    -   $-    1,122,311   $22,000   $12,342,344   $(55,921,451)   (7,956,077)

 

5

 

 

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   2026   2025 
   For the Nine Months Ended
September 30,
 
   2026   2025 
Cash Flows From Operating Activities:          
Net Loss  $(3,095,751)  $(2,835,732)
Adjustments to reconcile net loss to net cash used in operations          
Depreciation expense   18,768    17,511 
Net change in unrealized depreciation (appreciation) and depreciation in gold bullions   34,221    (76,509)
Gain on sale of gold bullions   -    (160,896)
Stock issued for services   400,000    834,600 
Imputed interest - related party   55,593    60,472 
Fair value of options issued for services   30,471    12,591 
Warrants issued/(cancelled) to consultants   333,661    195,911 
Provision for inventory valuation allowance   42,469    - 
Changes in operating assets and liabilities:          
(Increase) in accounts receivable   (3,000)   - 
(Increase) Decrease prepaid expenses   (11,614)   14,975 
(Increase) in inventory   (186,163)   (22,183)
Decrease in operating lease right-of-use, net   52,602    42,096 
Increase in accrued expenses and other payables - related party   651,243    620,913 
(Decrease) Increase in accounts payable   5,406    250 
Decrease in operating lease liabilities, current   (50,501)   (43,482)
Net Cash Used In Operating Activities   (1,722,595)   (1,339,483)
           
Cah Flows from Investing Activities          
Proceeds from sale of investment in gold   -    369,992 
Purchase of fixed assets   (56,386)   (3,783)
Net Cash Provided by Investing Activities   (56,386)   366,209 
           
Cash Flows From Financing Activities:          
Proceeds from Standby Equity Purchase Agreement   2,772,547    1,925,702 
Payment of debt offering costs   -    (10,000)
Principal payments on debt - related party   -    (50,000)
Net Cash Provided by Financing Activities   2,772,547    1,865,702 
           
Net Change in Cash and Cash Equivalents   993,566    892,428 
           
Cash and Cash Equivalents at Beginning of Period   1,790,236    673,264 
           
Cash and Cash Equivalents at End of Period  $2,783,802   $1,565,692 
           
Supplemental disclosure of cash flow information:          
           
Cash paid for interest  $-   $- 
Cash paid for taxes  $-   $- 
           
Supplemental disclosure of non-cash investing and financing activities:          
Adoption of lease standard ASC 842  $69,340   $140,038 
Common shares issued in connection with Standby Equity Purchase Agreement - Commitment Share fee  $-   $100,000 
Shares issuabel in connection with cashless warrant exercise  $142,526   $92,317 

 

6

 

 

Kraig Biocraft Laboratories, Inc.

Notes to Condensed Consolidated Financial Statements as of September 30, 2026

(Unaudited)

 

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.

 

In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all of the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2026 and the results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the operating results for the full fiscal year or any future period.

 

These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026.

 

Management acknowledges its responsibility for the preparation of the accompanying unaudited consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for the periods presented.

 

Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries.

 

On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary.

 

On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.

 

On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.

 

On January 24, 2024, the Company signed a memorandum of understanding with the Vietnam Sericulture Association (“VSA”) and the Lam Dong Agro-Forestry Research & Experiment Center (“LAREC”) to enhance sericulture in Vietnam through the expanded application of the Company’s spider silk silkworm technology.

 

On January 14, 2025, the Company was granted a new Investment Registration Certificate and an Enterprise Registration Certificate for its production operations in Vietnam. This registration formed a new subsidiary, Prodigy Silk Co., Ltd.

 

On January 12, 2026, the Company dissolved Prodigy Textiles Co., Ltd, and transferred all of its production operations into Prodigy Silk Co., Ltd. Vietnamese Law required a new business name for the Company’s new Enterprise Registration Certificate issued in 2025.

 

7

 

 

Foreign Currency

 

The assets and liabilities of Prodigy Textiles, Co., Ltd. and Prodigy Silk Co., Ltd. (the Company’s Vietnamese subsidiaries) whose functional currencies are the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period.

 

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of demand deposits at financial institutions, money market funds, and highly liquid investments with original maturities of three months or less.

 

As of September 30, 2026, and December 31, 2025, the Company had $2,783,802 and $1,790,236, in cash and cash equivalent accounts.

 

Accounts Receivable and Allowance for Credit Losses

 

The Company maintains current receivable amounts with most of its customers. The Company regularly monitors and assesses its risk of not collecting amounts owed by customers. This evaluation is based upon an analysis of current and past due amounts, along with relevant history and facts particular to the customer. The Company records its allowance for credit losses based on the results of this analysis. The analysis requires the Company to make significant estimates and as such, changes in facts and circumstances could result in material changes in the allowance for credit losses. The Company considers as past due any receivable balance not collected within its contractual terms. The Company provided $0 and $0, allowances for doubtful accounts as of September 30, 2026, and December 31, 2025, respectively.

 

As of September 30, 2026 and December 31, 2025, the Company had accounts receivable of $3,000 and $0, respectively, related to product sales during the period, none of which had been collected as of that date.

 

Loss Per Share

 

Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For September 30, 2026, and December 31, 2025, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive.

 

The computation of basic and diluted loss per share for September 30, 2026, and December 31, 2025 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive:

 

   September 30, 2026   December 31, 2025 
         
Stock Warrants (Exercise price - $0.001- $0.25/share)   56,285,714    72,285,714 
Stock Options (Exercise price - $0.1150/Share)   37,481,000    34,981,000 
Convertible Preferred Stock   3    3 
Common Stock Payable   1,122,311    1,122,311 
Total   94,889,028    108,389,028 

 

8

 

 

Research and Development Costs

 

The Company expenses all research and development costs as incurred, for which there is no alternative future use.

 

For the three months ended September 30, 2026, and 2025, the Company had $132,284 and $9,243, respectively, in research and development costs.

 

For the nine months ended September 30, 2026, and 2025, the Company had $263,354 and $97,007, respectively, in research and development costs.

 

Advertising Expense

 

The Company follows the policy of charging the costs of advertising to expense as incurred. There was no advertising expense in the three and nine months ended September 30, 2026, and 2025.

 

Income Taxes

 

The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life (The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations.

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07.

 

RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS

 

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (“ASU 2024-03”), which requires disclosure of disaggregated information about certain income statement expense line items in the notes to the financial statements on an interim and annual basis. ASU 2024-03 will be effective for the Company’s fiscal year ending November 30, 2028. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its condensed consolidated financial statements and disclosures.

 

9

 

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. This Update enhances the transparency and usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. The guidance also eliminates certain existing requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in this Update are effective for annual periods beginning after December 15, 2024. During the year ended March 31, 2026, the Company adopted ASU 2023-09. This adoption only impacted the disclosures and did not otherwise impact the condensed consolidated financial statements.

 

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

 

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03). The guidance requires disaggregated information about certain income statement expense line items on an annual and interim basis. This guidance will be effective for annual periods beginning with the year ending December 31, 2027 and for interim periods thereafter. The new standard permits early adoption and can be applied prospectively or retrospectively. We are evaluating the effect that this guidance will have on our financial statements and related disclosures.

 

In September 2025, the FASB issued ASU No. 2025-06, Intangibles: Goodwill and Other‒Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06). The guidance modernizes the accounting for software costs and enhances the transparency about an entity’s software costs. The guidance will be effective for the annual periods beginning with the year ending December 31, 2027 and for interim periods beginning January 1, 2028. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively, retrospectively, or under a modified transition approach. We are evaluating the effect that this guidance and do not expect the adoption of this guidance to have a material impact on our financial statements.

 

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (ASU 2025-11), which clarifies interim disclosure requirements and the applicability of Topic 270. The guidance will be effective for interim periods beginning January 1, 2028. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guidance to have a material impact on our financial statements

 

In December 2025, the FASB issued ASU No. 2025-10, Accounting for Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities (ASU 2025-10) to establish authoritative guidance on the recognition, measurement, and presentation of government grants received by business entities. The guidance will be effective for the annual periods beginning with the year ending December 31, 2028 and for interim periods beginning January 1, 2029. Early adoption is permitted. Upon adoption, the guidance can be applied using a modified prospective, modified retrospective, or under a retrospective approach. We are evaluating the effect that this guidance and do not expect the adoption of this guidance to have a material impact on our financial statements. We do not expect the adoption of this guidance to have a material impact on our financial statements.

 

The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

Equipment

 

The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life.

 

In accordance with FASB ASC No. 360, Property, Plant and Equipment, the Company carries long-lived assets at the lower of the carrying amount or fair value. Impairment is evaluated by estimating future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected undiscounted future cash flow is less than the carrying amount of the assets, an impairment loss is recognized. Fair value, for purposes of calculating impairment, is measured based on estimated future cash flows, discounted at a market rate of interest.

 

10

 

 

Fair Value of Financial Instruments

 

We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” (“ASC Topic 820-10”). ASC Topic 820-10 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). ASC Topic 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Level 1 instruments include cash and cash equivalents, account receivable, prepaid expenses, inventory and account payable and accrued liabilities. The carrying values are assumed to approximate the fair value due to the short term nature of the instrument.

 

The three levels of the fair value hierarchy under ASC Topic 820-10 are described below:

 

  ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at September 30, 2026, and December 31, 2025.
     
  ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
     
  ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms.

 

The following are the major categories of assets measured at fair value on a recurring basis: as of September 30, 2026, and December 31, 2025, using quoted prices in active markets for identical liabilities (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

 

The Company has consistently applied the valuation techniques in all periods presented. The following table presents the Company’s assets which were measured at fair value at September 30, 2026, and December 31, 2025:

 

   September 30, 2026   December 31, 2025 
   Fair Value Measurement Using   Fair Value Measurement Using 
   Level 1   Level 2   Level 3   Total   Level 1   Level 2   Level 3   Total 
                                 
Assets:                                        
Investment in gold  $460,038   $-   $-   $460,038   $494,259   $-   $-   $494,259 
Money market fund  $2,693,290   $-   $-   $2,693,290   $1,408,399   $-   $-   $1,408,399 
Total  $3,153,328   $-   $-   $3,153,328   $1,902,658   $-   $-   $1,902,658 

 

The Board of Directors, who serves as the Custodian, is responsible for the safekeeping of gold bullion owned by the Company.

 

Valuation of Gold Bullion

 

The investment in Bullion is classified as a level 1 asset, as the Company’s investment in Bullion is calculated using unadjusted quoted prices from primary market sources.

 

11

 

 

Gains and Losses on Gold Bullion

 

Fair value of the gold bullion held by the Company is based on that day’s London Bullion Market Association (“LBMA”) Gold Price PM. “LBMA Gold Price PM” is the price per fine troy ounce of gold, stated in U.S. dollars, determined by ICE Benchmark Administration (“IBA”) following an electronic auction consisting of one or more 30-second rounds starting at 3:00 p.m. (London time), on each day that the London gold market is open for business and published shortly thereafter.

 

The Company holds gold bullion as part of its strategy to manage inflation risk and diversify its assets. Upon acquisition, the Company elected the Fair Value Option under ASC 825-10, Financial Instruments – Fair Value Option to account for its investment in gold bullion. This election is irrevocable and was made to better reflect the Company’s intent to manage the assets based on fair value fluctuations.

 

Accounting Policy and Election

 

The Company follows the provisions of ASC 820, Fair Value Measurement (“ASC 820”). ASC 820 provides guidance for determining fair value and requires increased disclosure regarding the inputs to valuation techniques used to measure fair value. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The Company recognizes changes in fair value of the investment in Bullion as changes in unrealized gains or losses on investment in Bullion through the Statement of Operations.

 

In accordance with ASC 825-10, the Company has elected to measure its gold bullion at fair value with changes in fair value recognized in earnings. The gold bullion qualifies for the fair value option as it is a non-financial asset that is managed and evaluated on a fair value basis.

 

  ● The fair value option was elected at initial recognition of the gold bullion.
     
  ● Changes in fair value are recognized in “Other (Income) Expense, Net” in the Consolidated Statements of Operations.

 

For the three months ended September 30, 2026 and 2025, the Company recognized an unrealized gain of $19,386 and loss of $30,968, respectively, in “Other (income) expense, net” in the Consolidated Statements of Operations, reflecting changes in the fair value of gold bullion.

 

For the nine months ended September 30, 2026 and 2025, the Company recognized an unrealized loss of $34,221 and an unrealized gain of $76,509, respectively, in “Other (income) expense, net” in the Consolidated Statements of Operations, reflecting changes in the fair value of gold bullion.

 

Storage and Custody

 

The Company holds its gold bullion in a segregated vault operated by an independent third-party custodian. The Company periodically verifies the existence and condition of the gold through physical inspections and independent third-party audits.

 

The following tables summarize activity in gold bullion for the nine months ended September 30, 2026:

 

Nine Months Ended September 30, 2026  Ounces   Cost   Fair Value 
             
Balance December 31, 2025   110   $4,006   $494,259 
Net change in unrealized loss   -         (34,221)
Balance September 30, 2026   110   $4,006   $460,038 

 

12

 

 

Money Market Funds

 

Money market funds included in cash and cash equivalents and U.S. government-backed securities are measured at fair value based on quoted prices in active markets, which are considered Level 1 inputs. The Company’s policy is to recognize transfers in and/or out of the fair value hierarchy as of the date in which the event or change in circumstances caused the transfer.

 

Revenue Recognition

 

The Company was organized to develop high strength, protein-based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. The Company is in the early stages of commercialization and has generated limited revenue to date.

 

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. Revenue is recognized when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company applies the following five-step model:

 

●Identify the contract with a customer. A contract exists when the parties have approved it and are committed to perform, rights and payment terms are identifiable, the contract has commercial substance, and collection is probable.
   
●Identify the performance obligations. The Company’s performance obligations consist of the delivery of the Company’s products. Each distinct good or service is accounted for as a separate performance obligation.
   
●Determine the transaction price. The transaction price is the fixed amount stated in the customer’s contract or purchase order. The Company has not recorded any variable consideration, such as discounts, rebates, or rights of return, and its contracts contain no significant financing components.
   
●Allocate the transaction price. The Company’s contract currently contains a single performance obligation, so the entire transaction price is allocated to that obligation.
   
●Recognize revenue. Revenue is recognized at a point in time, when the product is delivered and control transfers to the customer.

 

Accounts receivables are recorded when the Company’s right to consideration becomes unconditional and are stated net of an allowance for expected credit losses, if any. No allowance was recorded at September 30, 2026.

 

Cost of Revenues

 

Cost of goods sold consists of the carrying value of inventory sold, including products provided to customers at no additional charge as part of a sales transaction. Inventory costs are determined using the first-in, first-out (“FIFO”) method and recognized as cost of goods sold when the related products are transferred to customers. Costs associated with research and development activities are excluded from cost of goods sold and recognized as research and development expenses.

 

Concentration of Credit Risk

 

The Company is exposed to credit risk in the normal course of business, primarily related to accounts receivable and cash and cash equivalents.

 

The Company at times has cash and cash equivalents in banks in excess of FDIC insurance limits. At September 30, 2026, and December 31, 2025, the Company had approximately $2,594,077 and $0, respectively in excess of FDIC insurance limits.

 

On March 12, 2023, the U.S. government took extraordinary steps to stop a potential banking crisis after the historic failure of Silicon Valley Bank, assuring all depositors at the failed institution that they could access all their money quickly, even as another major bank was shut down. The Company had no exposure to a failed bank. The Company averts risks associated with such a crisis by holding minimum cash balances required for uninterrupted operations, federal funds money market fund, and U.S. government-backed securities. As of September 30, 2026 and December 31, 2025, the Company held $2,693,290 and $1,408,399, respectively, million in a federal money market fund (the “Fund”) with an investment objective to seek to provide current income while maintaining liquidity and a stable share price of $1. The Fund invests at least 99.5% of its total assets in cash, U.S. government securities, and/or repurchase agreements that are collateralized solely by U.S. government securities or cash (collectively, government securities). As such it is considered one of the most conservative investment options offered.

 

As of September 30, 2026, 100% of its total accounts receivable was from one customer.

 

Original Issue Discount

 

For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to amortization of original issue discount in the consolidated statements of operations over the life of the debt.

 

Debt Issue Cost

 

Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument.

 

13

 

 

Investments without a Readily Determinable Fair Value (Cost Method)

 

Investments in nonmarketable entities in which the Company is not able to exercise significant influence, our “Cost Method Investments,” are accounted for at our initial cost, minus any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

 

The Company holds a 15% direct equity investment in Global Silk Solutions Joint Stock Company, a private Company. We received this investment in exchange for nominal consideration and carry the investment at $0 on September 30, 2026, and December 31, 2025, respectively.

 

Inventories

 

Inventory is stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out “FIFO” method and includes the purchase price and other costs incurred to bring the inventory to its present location and condition.

 

The Company’s inventory primarily consists of in-process materials such as wet and dry cocoons as well as reeled silk held for additional production processing and commercial sales. The Company periodically evaluates inventory for deterioration, damage, excess quantities, obsolescence and changes in expected future use or estimated net realizable value. When the carrying value of inventory exceeds its estimated net realizable value, the Company records a write-down to reduce the inventory to its estimated net realizable value.

 

Materials consumed in research and development activities are charged to research and development expenses when used. Materials acquired for a specific research and development project that have no alternative future use are expensed as incurred.

 

During the three months ended September 30, 2026, the Company recorded an inventory write-down of $9,655 to reduce the carrying value of certain inventory to its estimated net realizable value. The inventory write-down was included in research and development expense in the accompanying condensed consolidated statements of operations.

 

During the nine months ended September 30, 2026, the Company recorded an inventory write-down of $42,469 to reduce the carrying value of certain inventory to its estimated net realizable value. The inventory write-down was included in research and development expense in the accompanying condensed consolidated statements of operations.

 

At September 30, 2026 and December 31, 2025, inventory was $172,761 and $29,067, respectively, consisting of wet cocoons, dry cocoons and silk.

 

Segment Reporting

 

Operating segments are defined as components of an enterprise that have the following characteristics: (i) they engage in business activities from which they may earn revenue and incur expense, (ii) their operating results are regularly reviewed by the chief operating decision maker (“CODM”) for resource allocation decisions and performance assessment, and (iii) their discrete financial information is available. Our CODM is our Chief Executive Officer, who manages and allocates resources to our operations on a consolidated basis. We operate as one segment, and our operations are focused on developing high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. Segment information is further described in Note 9.

 

NOTE 2 GOING CONCERN

 

As reflected in the accompanying financial statements, the Company has a working capital deficiency of $8,110,368 and stockholders’ deficiency of $7,502,437 and used $1,722,595 of cash in operations for the nine months ended September 30, 2026. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

 

14

 

 

NOTE 3 EQUIPMENT

 

At September 30, 2026, and December 31, 2025, property and equipment, net, is as follows:

 

   September 30, 2026  

December 31, 2025

  

Estimated

Useful

Lives (Years)

 
Automobile  $55,105   $41,805    5 
Laboratory Equipment   179,799    138,332    5-10 
Office Equipment   8,879    7,260    5-10 
Leasehold Improvements   82,739    82,739    2-5 
                
Less: Accumulated Depreciation   (263,901)   (245,133)     
Total Property and Equipment, net  $62,621   $25,003      

 

Depreciation expense for the three months ended September 30, 2026, and 2025, was $5,444 and $5,992 respectively.

 

Depreciation expense for the nine months ended September 30, 2026, and 2025, was $18,768 and $17,511 respectively.

 

NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITY

 

We determine if an arrangement is a lease, or contains a lease, at inception and record the leases in our financial statements upon lease commencement, which is the date when the underlying asset is made available for use by the lessor.

 

We have a lease agreement with lease and non-lease components and have elected to utilize the practical expedient to account for lease and non-lease components together as a single combined lease component, from both a lessee and lessor perspective with the exception of direct sales-type leases and production equipment classes embedded in supply agreements. From a lessor perspective, the timing and pattern of transfer are the same for the non-lease components and associated lease component and, the lease component, if accounted for separately, would be classified as an operating lease.

 

We have elected not to present short-term leases on the balance sheet as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that we are reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because our lease does not provide an implicit rate of return, we used our incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments.

 

In general, leases, where we are the lessee, may include options to extend the lease term. These leases may include options to terminate the lease prior to the end of the agreed upon lease term. For purposes of calculating lease liabilities, lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise such options.

 

Lease expense for operating leases is recognized on a straight-line basis over the lease term as cost of revenues or operating expenses depending on the nature of the leased asset. Certain operating leases provide for annual increases to lease payments based on an index or rate. We calculate the present value of future lease payments based on the index or rate at the lease commencement date.

 

Differences between the calculated lease payment and actual payment are expensed as incurred. Amortization of finance lease assets is recognized over the lease term as cost of revenues or operating expenses depending on the nature of the leased asset.

 

15

 

 

Interest expense on finance lease liabilities is recognized over the lease term in interest expense.

 

Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $2,508 for conference facilities, mail, fax, and reception services located at our principal place of business.

 

On September 5, 2019, we signed a two year lease for a 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters. We pay an annual rent of $42,000 for year one of the lease and will pay $44,800 for year two of the lease. On April 16, 2021, the Company signed a two year amendment to this lease. Commencing on July 1, 2021 and ending on September 30, 2022, the Company paid an annualized rent of $42,000. From October 1, 2022 through September 30, 2023, the Company will pay an annual rent of $44,800. The Company recorded ROU asset of $79,862 and lease liability of $79,862 in accordance with the adoption of the new guidance. On October 1, 2023, the Company extended the terms of the lease through December 31, 2025. From October 1, 2023, through December 31, 2024, the Company paid an annual rent of $44,800. From October 1, 2024, through December 31, 2025, the Company will pay an annual rent of $47,600. The Company recorded ROU asset of $85,022 and lease liability of $85,022 in accordance with the adoption of the new guidance. On October 1, 2025, the Company extended the terms of the lease through September 30, 2028. The Company recorded ROU asset of $140,038 and lease liability of $140,038 in accordance with the adoption of the new guidance.

 

We pay annual rent as follows:

 

Lease Term  Annual Rent 
10/01/2025   09/30/2026   $50,008 
10/1/2026   09/30/2027   $52,808 
10/01/2027   09/30/2028   $55,608 

 

On July 1, 2021, the Company signed a 5-year property lease with the Socialist Republic of Vietnam, which consists of 6,000 square meters of space, which it leases at a current rent of approximately $8,645 per year.

 

On January 31, 2024, the Company signed a five year lease for a 700 square meter facility in Lam Dong, Vietnam that commenced on February 1, 2024, and ends on January 31, 2029. We pay an annual rent of ~$7,284 for year one and two of the lease. For years 3-5 the price will increase with Vietnam’s state land price bracket, not to exceed 10%. The Company recorded ROU asset of $30,084 and lease liability of $30,084 in accordance with the adoption of the new guidance. During the year ended December 31, 2024, the Company was in terminated its ROU lease arrangement.

 

The Company does not occupy or use the facility and therefore has determined to impair this asset as there is no future benefit.

 

On September 20, 2024, the Company signed a nine year lease for an 80 square meter facility in Lam Dong, Vietnam that commenced on September 20, 2024, and ends on December 31, 2030. The rent payments started after December 31, 2024. We pay the annual rent as follows:

 

Lease Term  Annual Rent 
9/20/2024   9/30/2026   $7,200.00 
10/1/2026   12/31/2027   $7,920.00 
1/1/2028   12/31/2030   $8,712.00 

 

If the agreement is renewed, price will increase with Vietnam’s state land price bracket, not to exceed 10%.In addition, the Company paid a security deposit of ~$3,657 for October 1, 2026, through December 31, 2027. Additional deposit of ~$3,657 will be due on January 1, 2028. The Company recorded ROU asset of $39,489 and lease liability of $39,489 in accordance with the adoption of the new guidance.

 

On January 1, 2026, the Company signed a two year lease for the land and single-story house in Lam Dong, Vietnam that commenced on January 1, 2026 and ends on December 31, 2027. Annual rent was paid in the amount of ~$6,840 and a deposit of $~760 was paid as of September 30, 2026. We pay the annual rent as follows:

 

Lease Term  Annual Rent 
1/1/2026   12/31/2026   $6,840.00 
1/1/2027   12/31/2037   $6,840.00 

 

16

 

 

The Company recorded ROU asset of $12,603 and lease liability of $12,603 in accordance with the adoption of the new guidance.

 

On March 31, 2026, the Company signed a three year lease for the land in Lam Dong, Vietnam that commenced on April 1, 2026 and ends on March 31, 2029. The Company paid rent for April, May and September 2026 in the amount of ~$1,710 and a deposit of $~570 as of September 30, 2026. We pay the annual rent as follows:

 

Lease Term  Annual Rent 
4/1/2026   3/31/2027   $6,840.00 
4/1/2027   3/31/2028   $6,840.00 
4/1/2028   3/31/2029   $6,840.00 

 

The Company recorded ROU asset of $18,190 and lease liability of $18,190 in accordance with the adoption of the new guidance.

 

On April 23, 2026, the Company signed a five year lease for the land in Lam Dong, Vietnam that commenced on May 1, 2026 and ends on April 30, 2031. The Company paid rent for May through December 2026 in the amount of ~$633 as of September 30, 2026. We pay the annual rent as follows:

 

Lease Term  Annual Rent 
5/1/2026   4/30/2027   $950.00 
5/1/2027   4/30/2028   $950.00 
5/1/2028   4/30/2029   $950.00 
5/1/2029   4/30/2030   $950.00 
5/1/2030   4/30/2031   $950.00 

 

The Company recorded ROU asset of $3,904 and lease liability of $3,904 in accordance with the adoption of the new guidance.

 

On April 28, 2026, the Company signed a three year lease for the facility in Lam Dong, Vietnam that commenced on May 1, 2026, and ends on April 30, 2028. The Company paid rent for May and September 2026 in the amount of ~$1,292 and a deposit of ~$1,292 as of September 30, 2026. We pay the annual rent as follows:

 

Lease Term  Annual Rent 
5/1/2026   4/30/2027   $7,752.00 
5/1/2027   4/30/2028   $7,752.00 

 

The Company recorded ROU asset of $14,283 and lease liability of $14,283 in accordance with the adoption of the new guidance.

 

On May 13, 2026, the Company signed a three year lease for the storage facility in Lam Dong, Vietnam that commenced on May 15, 2026 and ends on May 14, 2029. The Company paid rent for May through July 2026 in the amount of ~$570 and a deposit of ~$190 as of September 30, 2026. We pay the annual rent as follows:

 

Lease Term  Annual Rent 
5/14/2026   5/13/2027   $2,280.00 
5/14/2027   5/13/2028   $2,280.00 
5/14/2028   5/13/2029   $2,280.00 

 

17

 

 

The Company recorded ROU asset of $6,212 and lease liability of $6,212 in accordance with the adoption of the new guidance.

 

On August 13, 2026, the Company signed a three-year agreement for the warehouse and land lease in Lam Dong, Vietnam that commenced on August 20, 2026, and ends on October 19, 2029. The agreement provides for a two-month rent-free period through October 19, 2026, with rent commencing on October 20, 2026. The initial annual payment was due upon execution of the agreement, with subsequent annual payments due on October 17, 2027, and October 17, 2028. The Company paid annual rent for October 17, 2026, on August 20, 2026, in the amount of ~$5,320.

We pay the annual rent as follows:

 

Lease Term  Annual Rent 
8/20/2026   10/19/2026    Rent - free 
10/20/2026   10/19/2027   $5,320.00 
10/20/2027   10/19/2028   $5,320.00 
10/20/2028   10/19/2029   $5,320.00 

 

The Company recorded ROU asset of $14,283 and lease liability of $14,283 in accordance with the adoption of the new guidance.

 

The tables below present information regarding the Company’s operating lease assets and liabilities at September 30, 2026:

 

At September 30, 2026, and December 31, 2025, the Company had no financing leases as defined in ASC 842, “Leases.”

 

   September 30, 2026   December 31, 2025 
Assets          
           
Operating lease - right-of-use asset - non-current  $187,201   $170,463 
           
Liabilities          
           
Operating lease liability  $190,001   $171,162 
           
Weighted-average remaining lease term (years)   2.49    3.14 
           
Weighted-average discount rate   8%   8%
           
The components of lease expense were as follows:          
           
Operating lease costs          
           
Amortization of right-of-use operating lease asset  $64,465   $63,696 
Impairment of right of use asset  $-    - 
Total operating lease costs  $64,465   $63,696 
           
Supplemental cash flow information related to operating leases was as follows:          
           
Operating cash outflows from operating lease (obligation payment)  $48,717   $47,583 
Right-of-use asset obtained in exchange for new operating lease liability  $69,340   $140,038 
Impairment of right of use asset  $-    $  
Net  $-   $- 

 

18

 

 

Future minimum lease payments required under leases that have initial or remaining non-cancellable lease terms in excess of one year at September 30, 2026:

  

      
2026 (3 months)  $22,498 
2027   91,350 
2028   68,128 
2029   16,312 
2030 and beyond   12,883 
Total lease payments   211,171 
Less: amount representing interest   (21,170)
Total lease obligations   190,001 
      
Less: current portion of operating lease liability   (78,086)
Long-term portion operating lease liability  $111,915 

 

NOTE 5 NOTE PAYABLE – RELATED PARTY

 

Between September 6, 2016, and December 1, 2020 the Company received a total of $1,657,000 in loans from its founder and CEO. Pursuant to the terms of the loans, the advances bear an interest at 3%, is unsecured, and due on demand.

 

On January 26, 2022, the Company repaid $40,000 of the outstanding loan to its founder and CEO.

 

On August 26, 2025, the Company repaid $50,000 of the outstanding loan to its founder and CEO.

 

On December 16, 2025, the Company repaid $75,000 of the outstanding loan to its founder and CEO.

 

Total loan payable to the founder and CEO for as of September 30, 2026, is $1,492,000.

 

Total loan payable to the founder and CEO as of December 31, 2025, is $1,492,000.

 

During the nine months ended September 30, 2026, the Company recorded $55,593 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $42,792. As of September 30, 2026, total interest payable is $406,363.

 

During the nine months ended September 30, 2025, the Company recorded $60,472 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $44,482. As of September 30, 2025, total interest payable is $349,028.

 

During the year ended December 31, 2025, the Company recorded $79,275 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $59,026. As of December 31, 2025, total interest payable is $363,571.

 

As of September 30, 2026, total interest payable is $4,018,138.

 

As of December 31, 2025, total interest payable is $3,620,514.

 

19

 

 

NOTE 6 STOCKHOLDERS’ DEFICIT

 

(A) Common Stock Issued for Cash

 

On January 21, 2025, the Company entered into a Standby Equity Purchase Agreement with an investor granting the Company the rights to sell up to $10 Million of common stock.

 

During the nine months ended September 30, 2026, the Company sold 25,364,093 shares of common stock for total cash proceeds of $2,772,547.

 

During the year ended December 31, 2025, the Company sold 24,316,741 shares of common stock for total cash proceeds of $1,925,702, and paid stock offering costs of $10,000 and accrued an additional $15,000, which was netted from the total cash proceeds.

 

(B) Common Stock Issued for Services

 

Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant.

 

On September 2, 2026, the Company issued 5,000,000 shares of Common Stock to a consultant for services rendered having a fair value of $400,000, based upon the quoted closing price ($0.08/share).

 

On July 9, 2025, the Company issued 5,000,000 shares of Common Stock to a consultant for services rendered having a fair value of $434,600, based upon the quoted closing price ($0.09/share).

 

On July 16, 2025, the Company issued 5,000,000 shares of Common Stock to a consultant for services rendered having a fair value of $400,000, based upon the quoted closing price ($0.08/share) (See Note 7).

 

(C) Common Stock Warrants and Options

 

On May 4, 2026, the Company issued 5,959,847 shares of Common stock in connection with the cashless exercise of 6,000,000 warrants.

 

On March 14, 2025, the Company issued 2,157,710 shares of Common stock in connection with the cashless exercise of 2,181,518 warrants.

 

On July 1, 2025, the Company issued 314,636 shares of Common stock in connection with the cashless exercise of 318,482 warrants.

 

During the year ending December 31, 2025 the Company had 3,625,000 warrants issued to consultants expire. The Company recorded $458,020 as an offset to an expense and additional paid in capital for options expired. The net effect on equity was $0

 

During the nine months ending September 30, 2026, the Company had 2,000,00 warrants issued to consultants expire. The Company recorded $291,842 as an offset to an expense and additional paid in capital for options expired. The net effect on equity was $0

 

On March 25, 2021, in connection with the issuance of convertible notes, the Company issued warrants to purchase 8,000,000 shares of common stock at an exercise price of $0.25 per share. The fair value of the warrants at issuance was $435,228, which was recorded as a debt discount and credited to additional paid-in capital.  The warrants expired unexercised on March 25, 2026. As of September 30, 2026, no warrants were outstanding. The expiration had no impact on the Company’s condensed statements of operations.

 

On January 15, 2026 the Company issued a 10-year option to purchase 2,500,000 shares of common stock at an exercise price of $0.0825 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $143,283, based upon the Black-Scholes option-pricing model on the date of grant. Options vest on grant date. Options will be exercisable on January 15, 2036.

 

Expected dividends   0%
Expected volatility   86.00%
Expected term   10 years 
Risk free interest rate   3.77%
Expected forfeitures   0%

 

20

 

 

On October 22, 2025, the Company issued a 7-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.091 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $166,880, based upon the Black-Scholes option-pricing model on the date of grant. Options will vest upon certain triggering events as defined by the Company. Options will be exercisable on October 16, 2025. During the three months ended September 30, 2026, the Company recorded $ 11,920 as an expense for options issued.

 

  ● 600,000 vests after 6 months
     
  ● 1,400,000 vests after 18 months

 

 
Expected dividends   0%
Expected volatility   126.40%
Expected term   7 years 
Risk free interest rate   3.74%
Expected forfeitures   0%

 

On July 10, 2025, the Company issued a 5-year option to purchase 250,000 shares of common stock at an exercise price of $0.091 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $17,130, based upon the Black-Scholes option-pricing model on the date of grant. Options vest on grant date. Options will be exercisable on July 10, 2025. During the year ended December 31, 2025, the Company recorded $ 17,130 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   122.80%
Expected term   5 years 
Risk free interest rate   3.93%
Expected forfeitures   0%

 

On July 10, 2025, the Company issued a 5-year option to purchase 250,000 shares of common stock at an exercise price of $0.091 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $17,130, based upon the Black-Scholes option-pricing model on the date of grant. Options vest on grant date. Options will be exercisable on July 10, 2025. During the year ended December 31, 2025, the Company recorded $ 17,130 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   122.80%
Expected term   5 years 
Risk free interest rate   3.93%
Expected forfeitures   0%

 

On April 1, 2025, the Company issued a 7-year option to purchase 6,000,000 shares of common stock at an exercise price of $.08900 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $465,840, based upon the Black-Scholes option-pricing model on the date of grant. Options will vest upon certain triggering events as defined by the Company in the Employee Stock Option Plan, as long as the employee remains with the Company at vesting date. Options will be exercisable based on the following vesting provisions:

 

  ● 1,500,000 vests after 24 months
     
  ● 2,000,000 vests after 36 months
     
  ● 2,500,000 vests after 48 months

 

21

 

 

During the nine months ended September 30, 2026, the Company recorded $87,285 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   125.30%
Expected term   5.5 years 
Risk free interest rate   4.03%
Expected forfeitures   0%

 

On October 1, 2024, the Company issued a 7-year option to purchase 461,000 shares of common stock at an exercise price of $0.8685 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $33,533, based upon the Black-Scholes option-pricing model on the date of grant. Options will vest upon certain triggering events as defined by the Company in the Employee Stock Option Plan, as long as the employee remains with the Company at vesting date. Options will be exercisable on August 6, 2031. During the nine months ended September 30, 2026, the Company recorded $ 12,591 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   127.90%
Expected term   4.5 years 
Risk free interest rate   3.51%
Expected forfeitures   0%

 

On August 6, 2024, the Company issued a 7-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.1024 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $190,880, based upon the Black-Scholes option-pricing model on the date of grant. Options will vest upon certain triggering events as defined by the Company in the Employee Stock Option Plan, as long as the employee remains with the Company at vesting date. Options will be exercisable on August 6, 2031. During the nine months ended September 30, 2026, the Company recorded $20,443 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   133.80%
Expected term   4.5 years 
Risk free interest rate   3.73%
Expected forfeitures   0%

 

On August 6, 2024, the Company issued a 7-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.1024 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $190,880, based upon the Black-Scholes option-pricing model on the date of grant. Options will vest upon certain triggering events as defined by the Company in the Employee Stock Option Plan, as long as the employee remains with the Company at vesting date. Options will be exercisable on August 6, 2031. During the nine months ended September 30, 2026, the Company recorded $20,443 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   133.80%
Expected term   7 years 
Risk free interest rate   3.76%
Expected forfeitures   0%

 

22

 

 

On August 6, 2024, the Company issued a 7-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.1024 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $190,880, based upon the Black-Scholes option-pricing model on the date of grant. Options will vest upon certain triggering events as defined by the Company in the Employee Stock Option Plan, as long as the employee remains with the Company at vesting date. Options will be exercisable on August 6, 2031. During the nine months ended December 31, 2025, the Company recorded $20,443 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   133.80%
Expected term   7 years 
Risk free interest rate   3.76%
Expected forfeitures   0%

 

On August 6, 2024 the Company issued a 7-year option to purchase 50,000 shares of common stock at an exercise price of $0.1024 per share for services rendered. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The options had a fair value of $4,345, based upon the Black-Scholes option-pricing model on the date of grant. Options will vest upon certain triggering events as defined by the Company in the Employee Stock Option Plan, as long as the employee remains with the Company at vesting date. Options will be exercisable on August 6, 2026. During the nine months ended September 30, 2026, the Company recorded $1,267 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   133.80%
Expected term   4.5 years 
Risk free interest rate   3.73%
Expected forfeitures   0%

 

On December 13, 2023, the Company issued a 5-year option to purchase 6,000,000 shares of common stock at an exercise price of $0.04 per share to a related party for services rendered. The options had a fair value of $162,000, based upon the Black-Scholes option-pricing model on the date of grant. Options vest 20% on the grant date, 20% will vest on the second anniversary, 20% will vest on the third-year anniversary, 20% will vest on the fourth year anniversary as long as the employee remains with the Company at the end of each successive year for four years. Options will be exercisable on December 31, 2023, and for a period of 10 years expiring on December 13, 2033. During the nine months ended September 30, 2026, the Company recorded $24,300 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   133.30%
Expected term   6.25 years 
Risk free interest rate   4.04%
Expected forfeitures   0%

 

On December 13, 2023, the Company issued a 5-year option to purchase 4,000,000 shares of common stock at an exercise price of $0.04 per share to a related party for services rendered. The options had a fair value of $108,000, based upon the Black-Scholes option-pricing model on the date of grant. Options vest 20% on the grant date, 20% will vest on the second anniversary, 20% will vest on the third-year anniversary, 20% will vest on the fourth year anniversary as long as the employee remains with the Company at the end of each successive year for four years. Options will be exercisable on December 31, 2024, and for a period of 10 years expiring on December 13, 2033. During the nine months ended September 30, 2026, the Company recorded $16,200 as an expense for options issued.

 

Expected dividends   0%
Expected volatility   133.30%
Expected term   6.25 years 
Risk free interest rate   4.04%
Expected forfeitures   0%

 

23

 

 

Warrant activity as of September 30, 2026 is summarized as follows:

 

Warrants 

Number of

Warrants

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Term (Years)

  

Aggregate

Intrinsic

Value

 
Outstanding – December 31, 2025   72,285,714   $0.098    3.81   $1,733,000 
Exercisable – December 31, 2025   72,285,714   $0.098    3.81   $1,733,000 
Granted   -   $-    -    - 
Exercised   (6,000,000)  $(0.001)   -    - 
Cancelled/Forfeited   (10,000,000)  $0.2299    -    - 
Outstanding – September 30, 2026   56,285,714   $0.079    4.04   $1,913,480 
Exercisable – September 30, 2026   56,285,714   $0.079    4.04   $1,913,480 

 

As of September 30, 2026, the following warrants were outstanding:

  

Exercise Price

Warrants Outstanding

  

Warrants

Exercisable

  

Weighted Average

Remaining

Contractual Life

  

Aggregate

Intrinsic Value

 
              
$0.04    2,300,000    0.01   $161,000 
$0.12    12,500,000    0.29   $- 
$0.14    4,285,714    0.29   $- 
$0.04    4,000,000    6.21   $280,000 
$0.04    6,000,000    6.21   $420,000 
$0.04    10,000,000    6.21   $700,000 
$0.0825    5,000,000    6.03   $138,750 
$0.0825    5,000,000    6.86   $138,750 
$0.08    150,000    4.02   $4,500 
$0.08    500,000    4.00   $15,000 
$0.1024    2,000,000    4.86   $15,200 
$0.1024    2,000,000    4.86   $15,200 
$0.1024    2,000,000    4.86   $15,200 
$0.1024    50,000    4.86   $380 
$0.0910    250,000    3.75   $4,750 
$0.0910    250,000    3.75   $4,750 
$    $56,285,714        $1,913,480 

 

As of December 31, 2025, the following warrants were outstanding:

 

Exercise Price

Warrants Outstanding

  

Warrants

Exercisable

  

Weighted Average

Remaining

Contractual Life

  

Aggregate

Intrinsic Value

 
$0.001    6,000,000    0.41   $534,000 
$0.04    2,300,000    0.75   $115,000 
$0.2299    2,000,000    0.60   $- 
$0.25    8,000,000    0.23   $- 
$0.12    12,500,000    1.04   $- 
$0.14    4,285,714    1.04   $- 
$0.04    4,000,000    6.96   $200,000 
$0.04    6,000,000    6.96   $300,000 
$0.04    10,000,000    6.96   $500,000 
$0.0825    5,000,000    6.78   $38,750 
$0.0825    5,000,000    7.61   $38,750 
$0.08    150,000    4.76   $1,500 
$0.08    500,000    4.75   $5,000 
$0.1024    2,000,000    5.61   $- 
$0.1024    2,000,000    5.61   $- 
$0.1024    2,000,000    5.61   $- 
$0.1024    50,000    5.61   $- 
$0.0910    250,000    4.50   $- 
$0.0910    250,000    4.50   $- 
$     72,285,714        $1,733,000 

 

24

 

 

Options activity as of September 30, 2025 is summarized as follows:

 

Options 

Number of

Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Term (Years)

  

Aggregate

Intrinsic

Value

 
Outstanding – December 31, 2025   34,981,000   $0.114    13.11   $- 
Exercisable – December 31, 2025   34,981,000   $0.114    13.11   $- 
Granted   2,500,000   $.0825    9.80    - 
Exercised   -   $-    -    - 
Cancelled/Forfeited   -   $-    -    - 
Outstanding – September 30, 2026   37,481,000   $0.169    12.36   $- 
Exercisable – September 30, 2026   37,481,000   $0.169    12.36   $- 

 

For the nine months ended September 30, 2026, the following options were outstanding:

 

Exercise

Price

  

Options

Outstanding

  

Options

Exercisable

  

Weighted Average

Remaining Contractual

Life (in Years)

 
              
$0.169    37,481,000    28,750,500    12.36 

 

For the year ended December 31, 2025, the following options were outstanding:

 

Exercise

Price

  

Options

Outstanding

  

Options

Exercisable

  

Weighted Average

Remaining Contractual

Life (in Years)

 
              
$0.114    34,981,000    26,750,500    13.11 

 

(C) Amendment to Articles of Incorporation

 

On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows:

 

● Common stock Class A, unlimited number of shares authorized, no par value
● Common stock Class B, unlimited number of shares authorized, no par value
● Preferred stock, unlimited number of shares authorized, no par value

 

Effective December 17, 2013, the Company amended its articles of incorporation to designate a Series A no par value preferred stock. Two shares of Series A Preferred stock have been authorized.

 

On March 26, 2024, the Company increased the total authorized Series A preferred stock to four shares as approved by the board of directors.

 

25

 

 

On March 26, 2024, the Company issued one share of Series A preferred stock to Mr. Thompson, our CEO and founder. In consideration for the share of Series A preferred stock, Mr. Thompson paid twenty thousand dollars ($20,000), in the form of debt cancellation.

 

NOTE 7 COMMITMENTS AND CONTINGENCIES

 

Agreements

 

On November 10, 2010, the Company entered into an employment agreement with its CEO, effective January 1, 2011 through the December 31, 2015. The term of the agreement is a five year period at an annual salary of $210,000. There is a 6% annual increase. For the year ending December 31, 2015, the annual salary was $281,027. The employee is also to receive a 20% bonus based on the annual based salary. Any stock, stock options bonuses have to be approved by the board of directors. On January 1, 2016, the agreement was renewed with the same terms for another 5 years with an annual salary of $297,889 for the year ended December 31, 2016. On January 1, 2017, the agreement renewed with the same terms for another 5 years, but with an annual salary of $315,764 for the year ended December 31, 2017. On January 1, 2019, the agreement renewed again with the same terms for another 5 years. On January 1, 2025, the agreement renewed again with the same terms, but with an annual salary of $503,277 for the year ended December 31, 2025. On January 1, 2026, the agreement renewed again with the same terms, but with an annual salary of $533,474 for the years ended December 31, 2026. As of September 30, 2026, and December 31, 2025, the accrued salary balance is $4,649,579 and $4,399,253, respectively (See Note 8).

 

On January 20, 2015, the board of directors appointed Mr. Jonathan R. Rice as our Chief Operating Officer. Mr. Rice’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to an annual cash compensation of $120,000, which includes salary, health insurance, 401K retirement plan contributions, etc. The Company also agreed to reimburse Mr. Rice for his past educational expenses of approximately $11,000. In addition, Mr. Rice was issued a three-year warrant to purchase 2,000,000 shares of common stock of the Company at an exercise price of $0.001 per share (the “January 2015 Warrant”) pursuant to the employment agreement. Additionally, on May 28, 2015, the Company issued a three-year warrant to purchase 3,000,000 shares of common stock of the Company at an exercise price of $0.001 per share (the “May 2015 Warrant”) to Mr. Rice. The May 2015 warrant fully vested on October 28, 2016, and will expire on May 28, 2022. For the year ended December 31, 2015, the Company recorded $121,448 for the warrants issued to Mr. Rice. On January 14, 2016, the Company signed a new employment agreement with Mr. Rice. The employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to annual cash compensation of $140,000, which includes salary, health insurance, 401K retirement plan contributions, etc. In addition, Mr. Rice was issued a three-year warrant to purchase 6,000,000 shares of common stock of the Company at an exercise price of $0.001 per share pursuant to the employment agreement (the “May 2016 Warrant”). The May 2016 warrant fully vested on February 20, 2017 and will expire on May 20, 2026. On January 9, 2018, the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the January 2015 warrant to January 10, 2025 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020. On March 5, 2021, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2022. On February 25, 2022, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2023. On August 8, 2019, Mr. Rice was issued a set of three 5five-year warrants to purchase a total of 6,000,000 shares of common stock of the Company at an exercise price of $0.2299 per share pursuant to the employment agreement. On April 26, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $20,000 per year and issue a one-time $20,000 bonus. On August 15, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by an additional $20,000 per year. On October 12, 2026, the Company signed an agreement to increase Mr. Rice’s base salary by an additional $20,000 per year.

 

As of September 30, 2026, and December 31, 2025, the Company owes $9,066 and $5,892, respectively, to Mr. Rice for payroll payable.

 

26

 

 

On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. On January 14, 2025 the board of directors appointed Mr. Le as the president of Prodigy Silk. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to annual cash compensation of $60,000. In addition, Mr. Le was issued two 3three-year warrants to purchase 2,000,000 shares of common stock of the Company at an exercise price of $0.2299 per share. As of December 31, 2024, 2,000,000 warrants were cancelled by the Company. On December 13, 2023, the Company issued a 5-year option to purchase 4,000,000 shares of common stock at an exercise price of $0.04 per share to a related party for services rendered. The options had a fair value of $108,000, based upon the Black-Scholes option-pricing model on the date of grant. Options vest 20% on the grant date, 20% will vest on the second anniversary, 20% will vest on the third-year anniversary, 20% will vest on the fourth year anniversary as long as the employee remains with the Company at the end of each successive year for four years. Options will be exercisable on December 31, 2023, and for a period of 10 years expiring on December 13, 2033. As of September 30, 2026, and December 31, 2025, the accrued salary balance is $3,018 and $1,953, respectively.

 

On May 4, 2026, the Company entered into an agreement with public relations firm Oak Street Communications. Under the terms of the agreement, the Company agreed to pay compensation of $22,500 for public relations services.

 

On July 30, 2026, the Company entered into a second agreement with Oak Street Communications for additional public relations services covering the period from September 1, 2026, through November 30, 2026. Under the terms of the new agreement, the Company has agreed to pay a monthly retainer of $7,500, for total compensation of $22,500, payable monthly within 30 days of the invoice date. The agreement may be terminated by either party upon 15 days’ written notice.

 

On September 2, 2026, the Company entered into a six-month consulting agreement for marketing, public relations, and investor awareness services. Pursuant to the agreement, the Company agreed to issue 5,000,000 shares of its common stock as compensation for services, with an aggregate fair value of $400,000, based on the market price of the Company’s common stock on the measurement date. In addition, the agreement provides for monthly cash payments of $10,000 to cover marketing-related expenses, which may be terminated at any time (See Note 6 (B)).

 

Legal Matters

 

The Company may be involved in legal actions and claims arising in the ordinary course of business, from time to time, none of which at the time are considered to be material to the Company’s business or financial condition.

 

License Agreement

 

On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. In accordance with FASB ASC No 480, Distinguishing Liabilities from Equity, the Company determined that the present value of the payment of $120,000 that was due on December 26, 2007. As of September 30, 2026, and December 31, 2025, the outstanding balance is $65,292. For the three months ended September 30, 2026, the Company recorded $1,470 in interest expensed and related accrued interest payable.

 

Operating Lease Agreements

 

The Company’s operating lease commitments are described in Note 4 – Right-of-Use Assets and Lease Liabilities.

 

Revenue and Accounts Receivable Concentration

 

For the three months ended September 30, 2026, one customer accounted for 100% of the Company’s revenues.

 

For the nine months ended September 30, 2026, one customer accounted for 100% of the Company’s revenues.

 

As of September 30, 2026, one customer accounted for more than 10% of the Company’s total outstanding accounts receivable.

 

27

 

 

NOTE 8 RELATED PARTY TRANSACTIONS

 

Accounts payable and accrued expenses – related party consists of the following:

 

   As of
September 30, 2026
   As of
December 31, 2025
 
         
Accounts payable - related party  $302,376   $303,321 
Accrued expenses - related party   4,661,662    4,407,098 
Accrued interest - related party   4,018,138    3,620,514 
Total accounts payable and accrued expenses - related party  $8,982,176   $8,330,933 

 

Between September 6, 2016, and December 1, 2020, the Company received a total of $1,657,000 in loans from its founder and CEO. Pursuant to the terms of the loan, the advance bears an interest at 3%, is unsecured, and due on demand.

 

On August 26, 2025, the Company repaid $50,000 of the outstanding loan to its founder and CEO.

 

On January 26, 2022, the Company repaid $40,000 of the outstanding loan to its founder and CEO.

 

On December 16, 2025, the Company repaid $75,000 of the outstanding loan to its founder and CEO

 

Total loan payable to principal stockholder for as of September 30, 2026, is $1,492,000.

 

Total loan payable to this principal stockholder as of December 31, 2025, is $1,492,000.

 

On February 2, 2024, the Company repaid $90,000 of accrued expenses to its Chief Executive Officer.

 

During the nine months ended September 30, 2026, the Company recorded $55,593 as an in-kind contribution of interest related to the loan.

 

During the nine months ended September 30, 2025, the Company recorded $60,472 as an in-kind contribution of interest related to the loan.

 

As of September 30, 2026, total interest payable is $4,018,138.

 

As of December 31, 2025, total interest payable is $3,620,514.

 

As of September 30, 2026, and December 31, 2025, there was $302,376 and $303,321, respectively, included in accounts payable – related party, which is owed to the Company’s Chief Executive Officer for expenses paid on behalf of the Company.

 

As of September 30, 2026, and December 31, 2025, there was $4,661,662 and $4,407,098, respectively, included in accrued expenses – related party, which includes accrued salaries owed to the Company’s senior staff.

 

As of September 30, 2026, and December 31, 2025, there was $4,018,138 and $3,620,514, respectively, included in accrued interest – related party, which includes interest on accrued salary and accrued expenses owed to the Company’s Chief Executive Officer.

 

In aggregate as of September 30, 2026, and December 31, 2025, the Company owed $8,982,176 and $8,330,933, respectively to its related parties in accrued salaries and accrued interest.

 

As of September 30, 2026, and December 31, 2025, the Company owed $65,292 and $65,292, respectively, in royalty agreement payable to Chief Executive Officer.

 

28

 

 

NOTE 9 SEGMENT INFORMATION

 

We operate as one segment, and our operations are focused on developing high strength, protein-based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries

 

Our Chief Executive Officer, as the CODM, uses consolidated net loss to evaluate our expenditures and monitor budget versus actual results. The monitoring of budget versus actual results and cash on hand are used in assessing the performance of the segment and in establishing resource allocation across the organization.

 

Factors used in determining the reportable segment include the nature of our operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance.

 

Significant expenses within net loss include general and administrative, professional fees, officers’ salary, research and development, interest expense, interest income and other, net and income tax expense, which are each separately presented on our consolidated statements of operations.

 

29

 

 

The following table presents information about the segment’s loss for the three months ended September 30, 2026:

  

      
Revenue  $3,000 
Cost of Revenues   (4,320)
Gross Loss   (1,320)
      
Less:     
Employee expense   371,874 
Occupancy expense   24,435 
Research and development expense   132,284 
Professional services expense   55,720 
Warrants issued for services expense   73,372 
Issuance of common stock for services   400,000 
Depreciation and amortization expense   5,445 
Interest Expense   153,385 
Office expense   19,366 
Other segment expense (a)   51,451 
Other income   (25,769)
Unrealized investment on gold   (19,386)
Segment net loss   1,243,496 
      
Reconciliation of loss     
      
Adjustments and reconciling items   - 
      
Consolidated net loss  $1,243,496 

 

(a) Other segment items included in segment net loss include bank service charges, insurance, filing fees, meals, and other overhead expenses

 

The following table presents information about the segment’s loss for the three months ended September 30, 2025:

 

      
Revenue  $- 
      
Less:     
Employee expense   305,108 
Occupancy expense   15,833 
Research and development expense   30,034 
Professional services expense   18,532 
Warrants issued for services expense   936,639 
Depreciation and amortization expense   5,991 
Interest Expense   144,255 
Office expense   8,982 
Other segment expense (a)   112,770 
Interest income   (99,546)
Unrealized investment on gold   30,968 
Segment net loss   1,509,566 
      
Reconciliation of loss     
      
Adjustments and reconciling items   - 
      
Consolidated net loss  $1,509,566 

 

(a)

Other segment items included in segment net loss include bank service charges, insurance, filing fees, meals, and other overhead expenses

 

30

 

 

The following table presents information about the segment’s loss for the nine months ended September 30, 2026:

 

      
Revenue  $3,000 
Cost of Revenues   (4,320)
Gross Loss   1,320 
      
Less:     
Employee expense   1,044,076 
Occupancy expense   68,690 
Research and development expense   263,354 
Professional services expense   196,416 
Warrants issued for services expense   364,132 
Issuance of common stock for services   400,000 
Depreciation and amortization expense   18,768 
Interest Expense   453,217 
Office expense   70,913 
Other segment expense (a)   236,530 
Interest income   (55,886)
Unrealized investment on gold   34,221 
Segment net loss   3,095,751 
      
Reconciliation of loss     
      
Adjustments and reconciling items   - 
      
Consolidated net loss  $3,095,751 

 

(a) Other segment items included in segment net loss include bank service charges, insurance, filing fees, meals, and other overhead expenses

 

Segment Assets:

 

As of September 30, 2026, total segment assets amounted to $3,737,549.

 

The following table presents information about the segment’s loss for the nine months ended September 30, 2025:

 

      
Revenue  $- 
      
Less:     
Employee expense   1,015,073 
Occupancy expense   49,502 
Research and development expense   145,053 
Professional services expense   150,893 
Warrants issued for services expense   1,043,102 
Depreciation and amortization expense   17,511 
Interest Expense   426,589 
Office expense   29,553 
Other segment expense (a)   201,446 
Interest income   (166,481)
Unrealized investment on gold   (76,509)
Segment net loss   2,835,732 
      
Reconciliation of loss     
      
Adjustments and reconciling items   - 
      
Consolidated net loss  $2,835,732 

 

(a) Other segment items included in segment net loss include bank service charges, insurance, filing fees, meals, and other overhead expenses

 

As of September 30, 2025, total segment assets amounted to $2,356,596.

 

NOTE 10 SUBSEQUENT EVENTS

 

The Company has analyzed its operations subsequent to September 30, 2026 through the date these financial statements were issued, and other than those listed below, has determined that it does not have any material subsequent events to disclose.

 

On October 6, 2026, the Company entered into a six-month consulting agreement for marketing, public relations, and investor awareness services, effective October 12, 2026. Pursuant to the agreement, the Company issued 1,348,315 shares of its common stock as compensation for services, with an aggregate value of approximately $120,000, determined based on the closing market price of the Company’s common stock on October 6, 2026.

 

On October 7, 2026, the Company sold 100,000 shares of common stock for total cash proceeds of $9,025 pursuant to the Standby Equity Purchase Agreement.

 

On October 14, 2026, the Company sold 69,400 shares of common stock for total cash proceeds of $6,131 pursuant to the Standby Equity Purchase Agreement.

 

On October 21, 2026, the Company sold 312,500 shares of common stock for total cash proceeds of $25,234 pursuant to the Standby Equity Purchase Agreement.

 

On October 28, 2026, the Company sold 240,530 shares of common stock for total cash proceeds of $18,966 pursuant to the Standby Equity Purchase Agreement.

 

On November 3, 2026, the Company sold 150,242 shares of common stock for total cash proceeds of $8,248 pursuant to the Standby Equity Purchase Agreement.

 

On November 9, 2026, the Company sold 474,900 shares of common stock for total cash proceeds of $37,220 pursuant to the Standby Equity Purchase Agreement.

 

On November 13, 2026, the Company sold 200,000 shares of common stock for total cash proceeds of $15,720 pursuant to the Standby Equity Purchase Agreement. 

 

31

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

FORWARD-LOOKING INFORMATION

 

The following information should be read in conjunction with Kraig Biocraft Laboratories, Inc. and its subsidiaries (“we”, “us”, “our”, or the “Company”) condensed unaudited financial statements and the notes thereto contained elsewhere in this report. Information in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Form 10-Q that does not consist of historical facts, are “forward-looking statements.” Statements accompanied or qualified by, or containing words such as “may,” “will,” “should,” “believes,” “expects,” “intends,” “plans,” “projects,” “estimates,” “predicts,” “potential,” “outlook,” “forecast,” “anticipates,” “presume,” and “assume” constitute forward-looking statements, and as such, are not a guarantee of future performance.

 

Forward-looking statements are subject to risks and uncertainties, certain of which are beyond our control. Actual results could differ materially from those anticipated as a result of the factors described in the “Risk Factors” and detailed in our other Securities and Exchange Commission (“SEC”) filings. Risks and uncertainties can include, among others, international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to obtain sufficient financing to continue and expand business operations; the ability to develop technology and products; changes in technology and the development of technology and intellectual property by competitors; the ability to protect technology and develop intellectual property; and other factors referenced in this and previous filings. Consequently, investors should not place undue reliance on forward-looking statements as predictive of future results.

 

Because of these risks and uncertainties, the forward-looking events and circumstances discussed in this report or incorporated by reference might not transpire. Factors that cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described elsewhere in this report and in the “Risk Factors” section of our registration statement on Form S-1.

 

The Company disclaims any obligation to update the forward-looking statements in this report.

 

Overview

 

Kraig Biocraft Laboratories, Inc., a Wyoming corporation, is a corporation organized to develop high strength fibers using recombinant DNA technology for commercial applications including technical textiles. We use genetically engineered silkworms that produce spider silk proteins to create our recombinant spider silk. Applications include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics and more. We believe that we are a world leader in the research, development, and production of commercially scalable and cost-effective spider silk fiber. Our primary proprietary fiber technology utilizes natural and engineered variants of spider silk produced in domesticated mulberry silkworms. Our business brings twenty-first century biotechnology to the historical silk industry. We are introducing materials with innovative properties into an established commercial ecosystem of silkworm rearing, silk spinning, weaving, and manufacture of garments and other products.

 

We are using genetic engineering technologies to develop fibers with greater strength, resiliency, and flexibility for use in our target markets, including the specialty fiber and technical textile industries. We believe that the genetically engineered protein-based fibers we seek to produce have properties that are in some ways superior to the materials currently available in the marketplace. Production of our product in commercial quantities holds what we believe to be potential life-saving ballistic resistant material, which we believe is lighter, thinner, more flexible, and tougher than steel. Other potential applications for spider silk based recombinant fibers include use as structural material and for any application in which light weight and high strength are required. We believe that fibers made with recombinant protein-based polymers will make significant inroads into the specialty fiber and technical textile markets.

 

32

 

 

Through our technologies, the introduction of the gene sequence based on those found in native spider silk, results in a germline transformation and is therefore self-perpetuating. Our recombinant spider silk fibers incorporate the silk proteins found in spider silk with native silkworm silk proteins. This combination of native silkworm proteins combined with spider silk protein structures results in new and unique recombinant silk fibers. This technology is in essence a protein expression platform which has other potential applications including diagnostics and pharmaceutical production. Moreover, our technologies are “green” inasmuch as our fibers and textiles are derived from nature and do not use any petrochemicals as an input into the fibers.

 

The Report of Independent Registered Public Accounting Firm to our financial statements as of December 31, 2024, and as of December 31, 2025, include an explanatory paragraph stating that our net loss from operations and net capital deficiency at December 31, 2025, raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Plan of Operations

 

During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:

 

● We plan to accelerate and expand commercial-scale production of our recombinant spider silk.
   
● We plan to expand our research and development to accelerate our work in creating next generation materials and to improve the robustness of our recombinant spider silk lines.
   
● We plan to create a line of recombinant spider silk fashion wear either under our own brand name or in partnership with existing commercial entities.
   
● We plan to continue the expansion of our overseas production operations, including working with local contractors or cooperatives and the hiring of additional direct staff, as needed.
   
● We plan to accelerate our microbiology research and development to create more advanced materials. We plan to develop more advanced spider silk and non-spider silk based fibers for select target markets.
   
● We will consider buying an established revenue producing company in a compatible business, in order to broaden our financial base and facilitate the commercialization of our products; as of the date hereof, we have not had any formal discussion or entered into any definitive agreements regarding any such purchase.
   
● We plan to increase the breadth of our research to include protein expression platform technologies.
   
● We plan to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile, and other industries.
   
● We plan to actively pursue an uplist to a national exchange if such an opportunity presents itself.

 

Limited Operating History

 

We have not previously demonstrated that we will be able to expand our business through an increased investment in our research and development efforts. We cannot guarantee that the research and development efforts described in this filing will be successful. Our business is subject to risks inherent in growing an enterprise, including limited capital resources, risks inherent in the research and development process, risks inherent in working with living organisms, political and legal risks associated with transgenics, and possible rejection of our products in development.

 

If financing is not available on satisfactory terms, we may be unable to continue our research and development and other operations. Equity financing will result in dilution to existing stockholders.

 

33

 

 

Standby Equity Purchase Agreement

 

On January 21, 2025, we entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”). Capitalized terms used herein, but not otherwise defined, have the meaning ascribed to such terms in the SEPA, a copy of which is filed herewith as Exhibit 10.10. As of September 30, 2026, the Company issued a total of 54,166,681 shares of Common Stock in exchange for $5,246,613 under the SEPA.

 

Pursuant to the SEPA, the Company has the right to sell to the Investor up to $10 million of its shares of common stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. Sales of the shares of common stock to the Investor under the SEPA, and the timing of any such sales, are at the Company’s option, and the Company is under no obligation to sell any shares of common stock to the Investor under the SEPA except in connection with notices that may be submitted by the Investor, in certain circumstances as described below.

 

Upon the satisfaction of the conditions to the Investor’s purchase obligation set forth in the SEPA, including having a registration statement registering the resale of the shares of common stock issuable under the SEPA declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the SEPA is terminated to direct the Investor to purchase a specified number of shares of common stock (“Advance”) by delivering written notice to the Investor (“Advance Notice”). While there is no mandatory minimum amount for any Advance, it may not exceed an amount equal to 100% of the average of the daily traded amount during the five consecutive trading days immediately preceding an Advance Notice.

 

In addition to the satisfaction of the conditions, the Investor shall not be obligated to purchase or acquire, and shall not purchase or acquire, any common stock under the SEPA which, when aggregated with all other common stock beneficially owned by the Investor and its affiliates, would result in the beneficial ownership by the Investor and its affiliates (on an aggregated basis) of a number of shares of common stock exceeding 4.99% of the then outstanding voting power or number of common shares. In addition, in no event shall an Advance exceed the number of common shares registered in respect of the transactions contemplated hereby under the registration statement then in effect.

 

The Company paid the Investor a structuring fee in an amount of $25,000. Additionally, within three days of signing the SEPA (the “Effective Date”), the Company paid a commitment fee in an amount equal to 1.00% of the Commitment Amount (the “Commitment Fee”) consisting of such number of Common Shares that is equal to the Commitment Fee divided by the average of the daily VWAPs of the Common Shares during the 3 Trading Days immediately prior to the Effective Date (the “Commitment Shares”). All of the Commitment Shares have been registered.

 

The SEPA will automatically terminate on the earliest to occur of (i) 36-month anniversary of the Effective Date or (ii) the date on which the Investor shall have made payment of Advances pursuant to the SEPA for shares of common stock equal to the Commitment Amount. The Company has the right to terminate the SEPA at no cost or penalty upon five (5) trading days’ prior written notice to the Investor, provided that there are no outstanding Advance Notices for which shares of common stock need to be issued. Neither the Company nor the Investor may assign or transfer their respective rights and obligations under the SEPA, and no provision of the SEPA may be modified or waived other than by an instrument in writing signed by both parties.

 

The SEPA contains customary representations, warranties, conditions, and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.

 

The net proceeds received by the Company under the SEPA will depend on the frequency and prices at which the Company sells its shares of common stock to the Investor. The Company expects that any proceeds received from such sales to the Investor will be used for working capital and general corporate purposes.

 

34

 

 

Three months ended September 30, 2026, compared to the three months ended September 30, 2025

 

   Three Months Ended September 30,       % Change
Increase
 
   2026    2025   Change   (Decrease) 
NET REVENUES  $3,000   $-    3,000    100.00%
COSTS OF REVENUES   4,320    -    4,320    100.00%
Gross Profit   (1,320)   -    (1,320)   100.00%
OPERATING EXPENSES:                    
General and Administrative   752,243    1,199,955    (447,712)   -37.31%
Professional Fees   55,719    38,533    17,186    44.60%
Officer’s Salary   193,705    186,157    7,548    4.05%
Research and Development   132,284    9,243    123,041    1331.18%
Total operating expenses   1,133,951    1,433,888    (299,937)   -20.92%
Loss from operations   (1,135,271)   (1,433,888)   298,617    -20.83%
Interest expense   (153,385)   (144,255)   (9,130)   6.33%
Net change in unrealized appreciation on investment in gold bullion   19,386    (30,968)   50,354    -162.60%
Gain on sale of gold   -    98,427    (98,427)   100.00%
Interest income   25,774    1,118    24,656    2205.37%
Net Loss  $(1,243,496)  $(1,509,566)   266,070    -17.63%

 

Our revenue, operating expenses, and net loss from operations for the three month period ended September 30, 2026, as compared to the three month period ended September 30, 2025, were as follows - some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:

 

Net Revenues: During the three months ended September 30, 2026, we realized $3,000 of revenues from our business. During the three months ended September 30, 2025, we realized $0 of revenues from our business. The change in revenues between the quarter ended September 30, 2026, and September 30, 2025, was $3,000 or 100%.

 

Cost of Revenues: Costs of revenues for the three months ended September 30, 2026, were $4,320, as compared to $0 for the three months ended September 30, 2025, a change of $4,320 or 100%.

 

Gross Loss: During the three months ended September 30, 2026, we realized a gross loss of $1,320 as compared to $0 for the three months ended September 30, 2025, a change of $1,320 or 100%.

 

35

 

 

Research and development expenses: During the three months ended September 30, 2026, we incurred $132,284 of research and development expenses. During the three months ended September 30, 2025, we incurred $9,243 of research and development expenses. This was an increase of $123,041 or 1,331.18% in 2026 compared with the same period in 2025. This increase was due to an increase in research spending.

 

Professional Fees: During the three months ended September 30, 2026, we incurred $55,719 of professional expenses, which increased by $17,186 or 44.60% from $38,533 for the three months ended September 30, 2025. This increase was primarily due to an increase in professional fees and in investor relations services.

 

Officers Salary: During the three months ended September 30, 2026, officers’ salary expenses increased to $193,705 or 4.05% from $186,157 for the three months ended September 30, 2025. This change was primarily due to 6% annual increase for the Company’s CEO.

 

General and Administrative Expense: General and administrative expenses decreased by $447,712 or 37.31% to $752,243 for the three months ended September 30, 2026, from $1,199,955 for the three months ended September 30, 2025.

 

Our general and administrative expenses for the three months ended September 30, 2026, consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants and shares issued for services) of $555,962, travel of $15,435, office salary of $140,846, and consulting of $40,000 for a total of $752,243.

 

Our general and administrative expenses for the three months ended September 30, 2025, consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants and shares issued for services) of $960,183, travel of $18,684, and office salary of $83,444, and consulting of $137,644 for a total of $1,199,955.

 

Net Change in Unrealized Appreciation and Depreciation on Investment in Gold Bullion: Net change in unrealized appreciation on investment in gold bullion decreased by $50,354 to $19,386 for the three month period ended September 30, 2026, from appreciation of $30,968 for the three month period ended September 30, 2025. The increase was primarily due to a net change in unrealized appreciation on investment in gold bullion.

 

Interest Expense: Interest expense increased by $9,130 to $153,385 for the three month period ended September 30, 2026, from $144,255 for the three month period ended September 30, 2025. The increase was primarily due to interest on certain Company loans.

 

Interest Income: Interest income increased by $24,656 to $25,774 for the three month period ended September 30, 2026, from $1,118 for the three month period ended September 30, 2025. The increase was primarily due to an increase in interest on money market fund.

 

Gain from sale of investment in gold: Gain from sale of investment in gold decreased by $98,427 to $0 for the three months ended September 30, 2026 from $98,427 for the three months ended September 30, 2025. This decrease was due to the Company’s partial sale of its investment in gold.

 

Net Loss: Net loss decreased by $266,070, or 17.63%, to a net loss of $1,243,496 for the three month period ended September 30, 2026 from a net loss of $1,509,566 for the three month period ending September 30, 2025. This decrease in net loss was primarily attributable to increases in general and administrative expenses, professional fees, officers’ salary, with a slight offset in research and development fees.

 

36

 

 

Nine months ended September 30, 2026, compared to the nine months ended September 30, 2025

 

  

Nine Months Ended

September 30,

      

% Change

Increase

 
   2026   2025   Change   (Decrease) 
NET REVENUES  $3,000   $-    3,000    100.00%
COSTS OF REVENUES   4,320    -    4,320    100.00%
Gross Profit   (1,320)   -    (1,320)   100.00%
OPERATING EXPENSES:                    
General and Administrative   1,622,190    1,852,841    (230,651)   -12.45%
Professional Fees   196,416    145,193    51,223    35.28%
Officer’s Salary   580,924    557,084    23,840    4.28%
Research and Development   263,354    97,007    166,347    171.48%
Total operating expenses   2,662,884    2,652,125    10,759    0.41%
Loss from operations   (2,664,204)   (2,652,125)   (12,079)   0.46%
Interest expense   (453,217)   (426,589)   (26,628)   6.24%
Net change in unrealized appreciation on investment in gold bullion   (34,221)   76,509    (110,730)   -144.73%
Gain on sale of gold   -    160,896    (160,896)   100.00%
Interest income   55,891    5,577    50,314    902.17%
Net Loss  $(3,095,751)  $(2,835,732)   (260,019)   9.17%

 

Our revenue, operating expenses, and net loss from operations for the nine month period ended September 30, 2026, as compared to the nine month period ended September 30, 2025, were as follows - some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:

 

Net Revenues: During the nine months ended September 30, 2026, we realized $3,000 of revenues from our business. During the nine months ended September 30, 2025, we realized $0 of revenues from our business. The change in revenues between the quarter ended September 30, 2026, and September 30, 2025, was $3,000 or 100%.

 

Cost of Revenues: Costs of revenues for the nine months ended September 30, 2026, were $4,320, as compared to $0 for the nine months ended September 30, 2025, a change of $4,320 or 100%.

 

Gross Loss: During the nine months ended September 30, 2026, we realized a gross loss of $1,320, as compared to $0 for the nine months ended September 30, 2025, a change of $1,320 or 100%.

 

Research and development expenses: During the nine months ended September 30, 2026, we incurred $263,354 of research and development expenses. During the nine months ended September 30, 2025, we incurred $97,007 of research and development expenses. This was an increase of $166,347 or 171.48% in 2026 compared with the same period in 2025. This increase was due to an increase in research spending.

 

Professional Fees: During the nine months ended September 30, 2026, we incurred $196,416 of professional expenses, which increased by $51,223 or 35.28% from $145,193 for the nine months ended September 30, 2025. This increase was primarily due to an increase in professional fees and in investor relations services.

 

37

 

 

Officers Salary: During the nine months ended September 30, 2026, officers’ salary expenses increased to $580,924 or 4.28% from $557,084 for the nine months ended September 30, 2025. This change was primarily due to 6% annual increase for the Company’s CEO.

 

General and Administrative Expense: General and administrative expenses decreased by $230,651 or 12.45% to $1,622,190 for the nine months ended September 30, 2026, from $1,852,841 for the nine months ended September 30, 2025.

 

Our general and administrative expenses for the nine months ended September 30, 2026, consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants and shares issued for services) of $1,088,911, travel of $41,709, office salary of $351,570, and consulting of $140,000 for a total of $1,622,190.

 

General and administrative expenses increased by $385,430 or 26.27% to $1,852,841 for the nine months ended September 30, 2025, from $1,467,411 for the nine months ended September 30, 2024. Our general and administrative expenses for the nine months ended September 30, 2025, consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants and shares issued for services) of $1,278,606, travel of $45,005, office salary of $341,586 and consulting expense of $187,644 for a total of $1,852,841.

 

Net Change in Unrealized Appreciation and Depreciation on Investment in Gold Bullion: Net change in unrealized appreciation on investment in gold bullion decreased by $110,730 to $34,221 for the nine month period ended September 30, 2026, from appreciation of $76,509 for the nine month period ended September 30, 2025. The decrease was primarily due to a net change in unrealized appreciation on investment in gold bullion.

 

Interest Expense: Interest expense increased by $26,628 to $453,217 for the nine month period ended September 30, 2026, from $426,589 for the nine month period ended September 30, 2025. The increase was primarily due to interest on certain Company loans.

 

Gain from sale of investment in gold: Gain from sale of investment in gold decreased by $160,896 to $0 for the nine months ended September 30, 2026 from $160,896 for the nine months ended September 30, 2025. This decrease was due to the Company’s partial sale of its investment in gold.

 

Interest Income: Interest income increased by $50,314 to $55,897 for the nine month period ended September 30, 2026, from $5,577 for the nine month period ended September 30, 2025. The increase was primarily due to an increase in interest on money market fund.

 

Net Loss: Net loss increased by $260,019, or 9.17%, to a net loss of $3,095,751 for the nine month period ended September 30, 2026 from a net loss of $2,835,732 for the nine month period ending September 30, 2025. This increase in net loss was primarily attributable to increases in professional fees, officers’ salary, in research and development fees and offset by a decrease in general and administrative expenses.

 

Capital Resources and Liquidity

 

Our financial statements have been presented on the basis that we have a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As presented in the unaudited condensed financial statements, we incurred a net loss of $3,095,751 during the nine months ended September 30, 2026, and losses are expected to continue in the near term. The accumulated deficit is $59,804,823 at September 30, 2026. Refer to Note 2 for our discussion of stockholder deficit. We have been funding our operations through private loans and the sale of common stock in private placement transactions. Our cash resources are insufficient to meet our planned business objectives without additional financing. These and other factors raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of our company to continue as a going concern.

 

38

 

 

Management anticipates that significant additional expenditures will be necessary to develop and expand our business before significant positive operating cash flows can be achieved. Our ability to continue as a going concern is dependent upon our ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. At September 30, 2026, we had $2,783,802 of cash on hand. These funds are insufficient to complete our business plan and as a consequence, we will need to seek additional funds, primarily through the issuance of debt or equity securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in the case of equity financing.

 

Management has undertaken steps as part of a plan to improve operations with the goal of sustaining our operations for the next twelve months and beyond. These steps include (a) raising additional capital and/or obtaining financing; (b) controlling overhead and expenses; and (c) executing material sales or research contracts. There can be no assurance that the Company can successfully accomplish these steps, and it is uncertain that the Company will achieve a profitable level of operations and obtain additional financing. There can be no assurance that any additional financing will be available to the Company on satisfactory terms and conditions, if at all. As of the date of this Report, we have not entered into any formal agreements regarding the above.

 

In the event the Company is unable to continue as a going concern, the Company may elect or be required to seek protection from its creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy. To date, management has not considered this alternative, nor does management view it as a likely occurrence.

 

Cash and cash equivalents, total current assets, total assets, total current liabilities, and total liabilities as of September 30, 2026, as compared to December 31, 2025, were as follows:

 

   September 30, 2026   December 31, 2025 
Cash and Cash Equivalents  $2,783,802   $1,790,236 
Inventory  $172,761   $29,067 
Prepaid expenses  $58,140   $49,338 
Total current assets  $3,017,703   $1,868,641 
Total assets  $3,737,549   $2,565,540 
Total current liabilities  $11,128,071   $10,445,245 
Total liabilities  $11,239,986   $10,564,498 

 

At September 30, 2026, we had a working capital deficit of $8,110,368, compared to a working capital deficit of $8,576,604 at December 31, 2025. Current liabilities increased to $11,128,071 at September 30, 2026, from $10,445,245 at December 31, 2025, primarily as a result of accounts payable - related party.

 

For the nine months ended September 30, 2026, net cash used in operations of $1,722,595 was the result of a net loss of $3,095,751 offset by depreciation expense of $18,768, net change in unrealized depreciation in gold bullions of $34,221, warrants issuance of $333,661, options issued for services of $30,471, imputed interest on related party loans of $55,593, an increase in prepaid expenses of $11,614, an increase in inventory of $143,694, a decrease in operating lease right of use of $52,602, an increase of accrued expenses and other payables-related party of $651,243, increase in accounts payable of $5,406 and a decrease in operating lease liabilities of $50,501.

 

For the nine months ended September 30, 2025, net cash used in operations of $1,339,483 was the result of a net loss of $2,835,732 offset by depreciation expense of $17,511, net change in unrealized depreciation in gold bullions of $76,509, gain on sale of gold bullions of $160,896, stock issued for services of $834,600, warrants issuance of $195,911, options issued for services of $12,591, imputed interest on related party loans of $60,472, a decrease in prepaid expenses of $14,975, an increase in inventory of $22,183, a decrease in operating lease right of use of $42,096, an increase of accrued expenses and other payables-related party of $620,913, decrease in accounts payable of $24,750 and a decrease in operating lease liabilities of $43,482.

 

39

 

 

Net cash used in our investing activities were $56,386 and $366,209 for the nine months ended September 30, 2026, and September 30, 2025, respectively. During the nine months ended September 30, 2026 the Company had purchase of fixed assets of $56,386. During the nine months ended September 30, 205, the Company had net proceeds from the sale investment in gold of $369,992 and purchase of fixed assets of $3,783.

 

Our financing activities resulted in a cash inflow of $2,772,547 for the nine months ended September 30, 2026, which is represented by $2,772,547 proceeds from the sale of stock.

 

Our financing activities resulted in a cash inflow of $1,865,702 for the nine months ended September 30, 2025, which is represented by $1,925,702 proceeds from the sale of stock, $10,000 payment in debt offering costs and $50,000 repayment to note payable – related party.

 

Critical Accounting Policies

 

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2025, for disclosures regarding the Company’s critical accounting policies and estimates, as well as updates further disclosed in our interim financial statements as described in this Form 10-Q.

 

RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS

 

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (“ASU 2024-03”), which requires disclosure of disaggregated information about certain income statement expense line items in the notes to the financial statements on an interim and annual basis. ASU 2024-03 will be effective for the Company’s fiscal year ending November 30, 2028. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its condensed consolidated financial statements and disclosures.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. This Update enhances the transparency and usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. The guidance also eliminates certain existing requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in this Update are effective for annual periods beginning after December 15, 2024. During the year ended March 31, 2026, the Company adopted ASU 2023-09. This adoption only impacted the disclosures and did not otherwise impact the condensed consolidated financial statements.

 

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

 

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03). The guidance requires disaggregated information about certain income statement expense line items on an annual and interim basis. This guidance will be effective for annual periods beginning with the year ending December 31, 2027 and for interim periods thereafter. The new standard permits early adoption and can be applied prospectively or retrospectively. We are evaluating the effect that this guidance will have on our financial statements and related disclosures.

 

In September 2025, the FASB issued ASU No. 2025-06, Intangibles: Goodwill and Other‒Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06). The guidance modernizes the accounting for software costs and enhances the transparency about an entity’s software costs. The guidance will be effective for the annual periods beginning with the year ending December 31, 2027 and for interim periods beginning January 1, 2028. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively, retrospectively, or under a modified transition approach. We are evaluating the effect that this guidance and do not expect the adoption of this guidance to have a material impact on our financial statements.

 

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (ASU 2025-11), which clarifies interim disclosure requirements and the applicability of Topic 270. The guidance will be effective for interim periods beginning January 1, 2028. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guidance to have a material impact on our financial statements

 

40

 

 

In December 2025, the FASB issued ASU No. 2025-10, Accounting for Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities (ASU 2025-10) to establish authoritative guidance on the recognition, measurement, and presentation of government grants received by business entities. The guidance will be effective for the annual periods beginning with the year ending December 31, 2028 and for interim periods beginning January 1, 2029. Early adoption is permitted. Upon adoption, the guidance can be applied using a modified prospective, modified retrospective, or under a retrospective approach. We are evaluating the effect that this guidance and do not expect the adoption of this guidance to have a material impact on our financial statements. We do not expect the adoption of this guidance to have a material impact on our financial statements.

 

The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of our fiscal quarter ended September 30, 2026, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon those evaluations, management concluded that our disclosure controls and procedures were not effective as of September 30, 2026, to cause the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods prescribed by SEC, and that such information is accumulated and communicated to management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Going forward from this filing, the Company intends to work on establishing and maintaining disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

 

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Changes in Internal Control over Financial Reporting

 

During the quarter covered by this Report, there were no changes in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. However, due to the unauthorized access to our checking account for Prodigy Silk, we have implemented additional safeguards to our accounts (See “Note 9 – Loss from Unauthorized Transfer Activity” for further information). Although we continue to educate our management personnel to increase its ability to comply with the disclosure requirements and financial reporting controls and management oversight of accounting and reporting functions in the future, as we stated in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, we do not expect to remediate the weaknesses in our internal controls over financial reporting until the time when we start to commercialize a recombinant fiber or such time as we have sufficient cash flow to carry out our remediation plans.

 

41

 

 

Part II - Other Information

 

Item 1. Legal Proceedings

 

From time to time, the Company may become a party to litigation or other legal proceedings that it considers to be a part of the ordinary course of its business. To the best of our knowledge, the Company is not currently involved in any legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition, or results of operations; however, the Company may become involved in material legal proceedings in the future.

 

Item 1A. Risk Factors

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this item. A description of risk factors can be found on our registration statement on Form S-1 located through the SEC EDGAR system or on the company website www.kraiglabs.com/sec-filings/. Information contained on, or that can be accessed through, our website does not constitute a part of this report.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Information regarding any equity securities we have sold during the period covered by this Report that were not registered under the Securities Act of 1933, as amended is set forth below. Each such transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated by the SEC, unless otherwise noted. Unless stated otherwise: (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii) each of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable about our operations and financial condition; (iv) no underwriter participated in, nor did we pay any commissions or fees to any underwriter in connection with the transactions; and, (v) each certificate issued for these unregistered securities contained a legend stating that the securities have not been registered under the Securities Act and setting forth the restrictions on the transferability and the sale of the securities.

 

On September 2, 2026, the Company issued 5,000,000 shares of Common Stock to a consultant for services rendered having a fair value of $400,000, based upon the quoted closing price ($0.08/share).

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

(a) Not applicable.

 

(b) None.

 

(c) During the nine months ended September 30, 2026, no director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

42

 

 

ITEM 6. EXHIBITS

 

EXHIBIT INDEX

 

Exhibit No.   Description
3.1   Articles of Incorporation (1)
3.2   Articles of Amendment (2)
3.3   Articles of Amendment, filed with the Wyoming Secretary of State on November 15, 2013 (3)
3.4   Articles of Amendment, filed with the Wyoming Secretary of State on December 17, 2013 (4)
3.5   Bylaws (1)
4.1   Form of Warrant issued Mr. Jonathan R. Rice (5)
4.2   Form of Warrant issued pursuant to that certain Purchase Agreement dated as of March 8, 2019 (7)
4.3   Form of Convertible Debenture (8)
4.4   Form of Warrant (8)
4.5   Form of A&R Convertible Debenture (8)
10.1   Employment Agreement between Mr. Jonathan Rice and the Company (6)
10.2   Form of Purchase Agreement dated March 8, 2019 (7)
10.3   Form of Securities Purchase Agreement (8)
10.4   Form of Guaranty Agreement (8)
10.5   Form of Security Agreement (8)
10.6   Form of IP Security Agreement (8)
10.7   Form of Registration Rights Agreement (8)
10.8   Strategic Partnership Agreement (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed) (9)
10.9   Amendment (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed) (9)
10.10   Standby Equity Purchase Agreement dated as of January 21, 2025, by and between the Company and YA II PN, LTD. (10)
31.1   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2   Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1   Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
32.2   Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101.INS   Inline XBRL Instance Document (filed herewith)
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1. Incorporated by reference to our Registration Statement on Form SB-2 (Reg. No. 333-146316) filed with the SEC on September 26, 2007.
2. Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-162316) filed with the SEC on October 2, 2009.
3. Incorporated by reference to our Current Report on Form 8-K filed with the SEC on November 22, 2013.
4. Incorporated by reference to our Current Report on Form 8-K filed with the SEC on December 19, 2013.
5. Incorporated by reference to our Annual Report on Form 10-K filed with the SEC on March 31, 2015.
6. Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 21, 2015.
7. Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 11, 2019.
8. Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 26, 2021.
9. Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 26, 2021.
10. Incorporated by reference to Exhibit 10.1 our Current Report on Form 8-K filed with the SEC on January 21, 2025.

 

43

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned thereunto duly authorized.

 

  Kraig Biocraft Laboratories, Inc.
  (Registrant)
   
Date: November 16, 2026 By: /s/ Kim Thompson
    Kim Thompson
    President, Chief Executive Officer and
    Chief Financial Officer (Principal Executive Officer and
    Principal Financial and Accounting Officer)

 

44

 

Keep reading